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Activation of EGFR and IR/IGF-1R leads to recruitment of mTORC2 to the plasma 
membrane via the PH domain of the mTORC2 partner protein mSin1. mTORC2 
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Ragulator and Rag GTPases, which recruits mTORC1 (via Raptor) to the lysosomal 
surface. ........................................................................................................................... 50 
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mTORC1 (48). mTOR also phosphorylates Raptor S859 with no defined function (47). 
AMPK phosphorylates Raptor S722 and S792 to suppress mTORC1 during energetic 
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Ku-0063794 (Ku) [100 nM] (30 min) and stimulated without (-) or with (+) poly(I:C) [30 
mg/mL] (1 hr.). Whole cell lysates were immunoblotted with the indicated antibodies. 106 
Figure 2.36: mTOR S2159 phosphorylation and TBK1 activity both promote 
mTORC2 signaling in primary BMDMs in response to poly(I:C). Primary bone 
marrow derived macrophages (BMDMs) derived from Mtor+/+ and MtorA/A mice were 
cultured in complete media (DMEM/FBS [10%]), pre-treated with Ku-0063794 [100 nM] 
(30 min) or amlexanox [100 mM] (1 hr), and stimulated without (-) or with (+) poly(I:C) 
[30 mg/mL] (10 min). WCLs were immunoblotted with the indicated antibodies. ......... 107 
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Figure 2.37: mTOR S2159 phosphorylation is required for mTORC2 signaling in 
mouse spleen tissue in response to poly(I:C) treatment in vivo. Mtor+/+ and MtorA/A 
mice were fasted 5 hr and injected intraperitoneally with poly(I:C) [10 mg/kg-BW] (2 hr). 
Spleen tissue was isolated, homogenized, and analyzed by western blotting with the 
indicated antibodies. ..................................................................................................... 107 





The mechanistic target of rapamycin (mTOR) senses diverse intracellular and 
extracellular cues to control key fundamental cellular processes, including cell growth 
and proliferation, cell survival, and metabolism. Consequently, aberrant mTOR activity 
contributes to various pathological diseases, including cancer, type 2 diabetes, and 
autoimmune diseases. mTOR nucleates the catalytic core of two multimeric complexes: 
mTOR complex 1 (mTORC1) and mTORC2. mTORC1 integrates nutrient and growth 
factor cues to promote cell growth, cell cycle progression, and anabolic processes, 
marked by increases in protein, lipid, and nucleotide biosynthesis. Growth factors and 
energetic stress activate mTORC2, which promotes cell survival and regulates 
metabolism. While upstream regulation of mTORC1, including the environmental stimuli 
and associated signaling intermediates, is far more comprehensively characterized, 
upstream regulation of mTORC2 remains woefully ill-defined.  
The noncanonical IKK-related kinases, Tank-binding kinase 1 (TBK1) and IKKe, 
initiate the innate immune response to circumvent pathogenic infection by integrating 
signals from various pattern recognition receptors’ detection of microbial-derived 
antigens. TBK1 and IKKe, in turn, phosphorylate and activate IRF-3/7 transcription 
factors to drive interferon beta (IFNb) production to promote eradication of infectious 
agents. Prior work from our lab identified TBK1 as a novel mTOR S2159 kinase. In 
macrophages, TBK1-mediated phosphorylation of mTOR S2159 within mTORC1 was 
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found to promote IRF-3 nuclear translocation and IFNb production, and EGF-stimulated 
mTORC1 signaling was reduced in mouse embryonic fibroblasts (MEFs) lacking TBK1 
or wild type MEFs treated with the TBK1 inhibitor amlexanox. While studying TBK1-
mediated activation of mTORC1, we also observed reduced EGF-stimulated 
phosphorylation of Akt S473, a well-established mTORC2 substrate. Here we 
demonstrate that TBK1-mediated phosphorylation of mTOR on S2159 increases 
mTORC2 intrinsic kinase activity and downstream signaling to Akt S473 in response to 
EGF, and, more broadly, mTOR S2159 phosphorylation promotes mTORC2 and 
mTORC1 signaling in response to a broader array of growth factors (EGF, FBS, PDGF, 
and insulin). Additionally, we demonstrate that mTOR S2159 phosphorylation promotes 
TLR-3-mediated mTORC2 and mTORC1 signaling in response to the synthetic dsRNA 
mimetic, poly (I:C). Mechanistically, TBK1 interacts with mTORC2 in intact cells and 
phosphorylates mTOR S2159 within mTORC2 in vitro. These results contribute 
important mechanistic insight toward our poor understanding of the upstream regulation 
of mTORC2. More importantly, since aberrant TBK1 and mTORC2 activity have both 
been implicated in pathological diseases, most notably obesity-driven type 2 diabetes 
and oncogenesis, the TBK1-mTORC2 axis may represent an attractive therapeutic 
target for such diseases. 









1.1 Historical identification of rapamycin and mTOR  
The mechanistic target of rapamycin (mTOR) is an evolutionarily conserved 
eukaryotic serine/threonine protein kinase. mTOR functions as an environmental sensor 
by virtue of its ability to monitor fluctuations in environmental conditions and modulate 
cellular processes, such as cell growth and metabolism, appropriately to maintain 
homeostasis. The identification of mTOR dates back to the 1960s where researchers in 
Rapa Nui (Easter Island) happened upon a unique compound produced by the 
bacterium, Streptomyces hygroscopicus, present in their soil isolate (1). Shortly 
thereafter named rapamycin, this compound was found to possess robust anti-
proliferative, anti-fungal, anti-tumor, and immunosuppressive properties (1-4). 
Unfortunately, nearly three decades would elapse before rapamycin’s intracellular target 
and mechanism of action would be discovered. Rapamycin binds the intracellular 
receptor and immunophilin, FKBP12, a cis-trans peptidyl-prolyl isomerase, to form a 
functional ternary complex (5,6). This rapamycin-FKBP12 complex docks to the 
FKBP12-rapamycin binding (FRB) domain on mammalian mTOR (amnio acids E2015-






1.2  mTORC1 and mTORC2 partner proteins and structure 
mTOR is a member of the phosphoinositide 3 kinase (PI3K)-like kinase family of 
serine/threonine protein kinases (11,12). In cells, through its association with both 
shared and unique partner proteins, mTOR comprises the catalytic core of two known 
multimeric complexes known as mTOR complex 1 (mTORC1) and mTORC2. The 
partner proteins that are common to both complexes include mammalian lethal with 
Sec13 protein 8 (mLST8) (alias: G-protein b-subunit like protein (GbL)) and DEP-
domain containing mTOR interacting protein (DEPTOR) (12,13). The unique partner 
proteins conveniently permit the biochemical differentiation, isolation, and analysis of 
each complex. mTORC1-exclusive partner proteins include Raptor (regulatory protein 
associated with mTOR) and PRAS40 (proline rich Akt substrate of 40 kDa) (12,14-16). 
Raptor confers dual functions on mTORC1, first by serving as an obligate scaffold 
partner to maintain complex stability and bind mLST8, and second, by facilitating 
mTORC1 recruitment of substrates via their TOR signaling (TOS) motifs, as well as 
recruitment of mTORC1 itself to distinct subcellular locations for activation (14,17,18). 
PRAS40 inhibits mTORC1, but this inhibition is relieved following insulin stimulation, 
which induces Akt-mediated phosphorylation and subsequent dissociation of PRAS40 
from the complex (19-21). Cryo-EM approaches indicate that mTORC1 exists in cells as 
a dimer with an apparent rhombus-like or “logenze” shape, with key binding contacts 
formed between Raptor, mTOR, and the mTOR HEAT repeats (22,23).  
mTORC2-specific partner proteins include Rictor (rapamycin insensitive 





associated with rictor 1/2) (24-29). Rictor and mSin1 are obligate scaffolding partners of 
mTORC2. Genetic ablation of Rictor profoundly destabilizes mTORC2 and reduces its 
activity in cells (30). mSin1 harbors the lipid-binding pleckstrin homology (PH) domain, 
which proves important for mTORC2’s recruitment to the plasma membrane in 
response to insulin where it phosphorylates and activates Akt (31). Activation of insulin 
or IGF-1 receptor induces phosphorylation of specific tyrosines within the receptor’s 
intracellular domains, which enables phosphatidylinositol 3 kinase (PI3K) to dock at the 
phosphotyrosines either directly, via the regulatory p85 subunit, or through the Src 
homology 2 (SH2) domains of co-adaptors (Fig 1.2) (32,33). PI3K recruitment permits it 
to catalyze the conversion of phosphatidylinositol 4,5 bisphosphate (PIP2) into 
phosphatidylinositol 3,4,5 triphosphate (PIP3) via pehosphorylation of the 3’ hydroxyl 
moiety of inositol ring-bearing lipids (Fig 1.2) (32-34). The generation of PIP3 on the 
inner leaflet of the plasma membrane facilitates recruitment of mTORC2, via the 
pleckstrin homology (PH) domain of mSin1, and Akt/protein kinase B (PKB), also via its 
PH domain, effectively relieving mSin1-mediated inhibition of mTORC2 and enabling it 
to phosphorylate Akt on its hydrophobic motif on S473 (11,35) (Fig1.2).  
mTORC2 is resistant to acute rapamycin treatment; however, chronic 
administration of rapamycin inhibits mTORC2 activity by disrupting mTORC2 complex 
integrity, a hypothesized consequence of ubiquitous rapamycin-FKBP12 complexes 
binding to newly synthesized mTOR and impeding its incorporation into new mTORC2 
complexes (12,36). Recent cryo-EM studies reveal incredible insight into mTORC2 





to mTORC1, mTORC2 also assumes a rhomboid dimeric structure, with mTOR-mTOR 
interactions forming a more compact conformation (37,38). In addition, the N-terminal 
helical rich clusters of Rictor bind mTOR, and mSin1 binds near the FRB domain and 
active site of mTOR, which imparts the steric hinderance that excludes rapamycin-
FKBP12 from the active site (37,38). These unique partner proteins permit 
differentiation between mTORC1 and mTORC2, play active roles in distinct regulation of 
both complexes, and confer distinct cellular functions on each complex.   
 
1.3 mTORC1: signaling pathways, substrates, and cellular functions 
mTORC1 senses a diverse array of intracellular and extracellular stimuli, 
including growth factors, hormones, nutrients (i.e. amino acids and glucose), cytokines, 
hypoxic factors, and high AMP levels (indicative of deficient cellular energy) (57-60). 
These stimuli activate numerous upstream pathways, all of which converge on 
mTORC1, through a central signaling node and inhibitor of mTORC1 known as the 
Tuberous Sclerosis Complex (TSC), to either activate or inhibit mTORC1. Upstream 
pathways that activate mTORC1 include the Ras/Raf/MAPK and PI3K/Akt pathways, 
which are activated downstream of growth factor-stimulated receptor tyrosine kinases 
(RTK) (Fig 1.2) (12,57). Conversely, upstream pathways that attenuate mTORC1 
signaling include DNA damage-induced activation of the tumor suppressor p53; 
energetic stress-induced activation of AMP activated protein kinase (AMPK); and 





and associated pathways do so by phosphorylating and inhibiting TSC, mTORC1 
inhibiting signals do so by phosphorylating and activating TSC.  
Growth factors such as epidermal growth factor (EGF) and insulin/insulin-like 
growth factor 1 (IGF-1) engage their cognate RTK to activate either the mitogenic 
Ras/Raf/MAPK pathway or the PI3K pathway (Fig 1.2) (32,33,62). In terms of the 
Ras/Raf/MAPK pathway, p90 ribosomal S6K (p90 RSK) and ERK1/2 phosphorylate 
TSC2 on inhibitory sites to relieve its suppression of mTORC1 (Fig 1.5) (63,64). In 
terms of the PI3K pathway, growth factor activated insulin/IGF-1 receptor recruits 3’-
phosphoinositide-dependent kinase 1 (PDK1) and Akt/protein kinase B (PKB) via their 
pleckstrin homology (PH) domains (Fig 1.2) (32,34,65).This coordinated localization 
enables PDK1 to directly phosphorylate Akt on its activation loop site on T308, and Akt 
inhibits TSC2 through multi-inhibitory site phosphorylation (Fig 1.2) (66-68). 
The TSC is a heterotrimeric complex comprised of three proteins: TSC1 
(hamartin), TSC2 (tuberin), and TBC1D7 (69,70). TSC was originally identified as a 
tumor suppressor after inactivating mutations in TSC1 and TSC2 were found to cause 
the formation of benign tumors on diverse organs such as the brain and kidneys (70). 
Akt-mediated phosphorylation of TSC2 (on S939 and T1462 in humans) induces 
dissociation of the TSC complex from the lysosomal membrane, thereby relieving its 
antagonistic effect on mTORC1; TSC fulfills this function by exerting its GTPase 
activating protein (GAP) activity toward the GTPase Rheb (Ras homolog enriched in 
brain), stimulating the conversion of active GTP-bound Rheb to inactive GDP-bound 





mechanism that likely involves a large conformational change in mTORC1 induced by 
Rheb binding near the mTOR kinase domain, effectively positioning critical active site 
residues for efficient catalysis (20,73,74,77,78).  
In addition to growth factors, mTORC1 also senses nutrients (amino acids) via 
rigorously deciphered intricate mechanisms. Nutrient deprivation of cells confines 
mTORC1 to the cytoplasm, whereas nutrient stimulation induces translocation of 
mTORC1 to the lysosome; mTORC1 remains tethered to the lysosome in the presence 
of amino acids through its interaction with the Rag-GTPases via an emanating claw-like 
structure on Raptor (79-82). Indeed, irreversible targeting of mTORC1 (via Raptor) to 
the lysosome uncouples mTORC1 activation from amino acid availability (59,83). The 
Rag-GTPases exist as obligate heterodimers that are regulated by multiple recently 
identified nutrient-binding proteins, among them Sestrin2, a direct leucine sensor, and 
CASTOR1, a direct arginine sensor (59,79,80,84-86) (Figure 1.5). Leucine binds 
Sestrin2 via a pocket that exploits specific charged residues on leucine to effectively 
engage a specific hydrophobic group (87). One GTP-bound Rag A or B binds one GDP-
bound Rag C or D to yield a competent heterodimer (84). The Rags are essential for 
mTORC1 responsiveness to acute shifts in amino acid concentrations, as constitutively 
active Rag alleles irreversibly tether mTORC1 to the lysosome regardless of amino 
acids depletion (59).  
A large five member complex known as the Ragulator or LAMTOR complex 
consists of LAMTOR1 (p18), LAMTOR2 (p14), LAMTOR3 (MP1), and LAMTOR4 





vacuolar H+ adenosine triphosphatase ATPase (v-ATPase) represent a key nexus 
between amino acid-induced mTORC1 activation. Amino acid starvation promotes 
engagement between the catalytic V1 ATPase subunit and the V0 proton pump subunit, 
while amino acid repletion disrupts this interaction, and an intralysosomal acidic pH 
proves essential for v-ATPase complex assembly (89). Also, using an eloquent in vitro 
biochemical reconstitution approach, Zoncu et al demonstrated a requirement for a 
sufficient intralysosomal amino acid pool in the ability of Raptor to interact with 
lysosome-associated Rag B/C as well as amino acid-induced activation of mTORC1 
(90). Importantly, v-ATPase activity appears to be important for the dynamic changes in 
interactions observed between the Ragulator/LAMTOR complex and the v-ATPase 
complex in response to amino acids (90). Specifically, the Ragulator/LAMTOR 
interaction, via its p18 and p14 subunits, with the v-ATPase V1 subunit is weakened 
following amino acid stimulation of amino acid starved cells (90).  
Additionally, through its cytoplasmic tail, the transmembrane-spanning 
intralysosomal arginine sensor SLC38A9 was shown to promote activation of the Rag 
GTPases by disrupting the lysosomal folliculin complex (LFC) comprised of three 
constituents: inactive Rag GTPase, Ragulator/LAMTOR, and folliculin (FLCN)-folliculin-
interacting protein 2 (FNIP2) (91). Specifically, SLC38A9-mediated disruption of the 
LFC permits FLCN-FNIP2 to exert its GAP activity toward GTP-bound Rag C, effectively 
relieving the locked, inactive state of the Rag GTPase (91). Interestingly, Shen et al 
revealed a uniquely distinct mechanism by which, through a coordinated effort, the 





Specifically, the Ragulator/LAMTOR exerts atypical guanine nucleotide exchange factor 
(GEF) activity toward GTP-bound Rag C, while, following arginine engagement, 
SLC38A9 directs its GEF function toward GDP-bound Rag A to yield an active Rag 
GTPase heterodimer (92). These studies support a model where cellular sensing of 
amino acids initiates within the lysosomal lumen, culminating in the activation of 
mTORC1. However, the report of two different mechanisms underlying the production of 
active Rag GTPase heterodimers warrants further investigation into this matter.  
In addition to, but unlike Sestrin2 and CASTOR1, SLC38A9, through interaction 
with the Ragulator (via its initial 119 N-terminal residues) and Rag GTPases and in an 
intralysosomal arginine-dependent manner, senses and exports intralysosomal amino 
acids obtained from the catabolic degradation of cellular proteins to free up free amino 
acids for energy and to re-activate mTORC1 (93-96). Note that SLC38A9 is particularly 
important for the export of leucine, which, with arginine, represent the two most potent 
activators of mTORC1 (59,96).   
Several additional regulatory proteins also compose the current amino acid 
sensing mTORC1 pathway. The trimeric GATOR1 complex, composed of DEPDC5 
(DEP domain containing 5), Npr12 (nitrogen permease regulator 2-like protein), and 
Npr13, exerts its GAP activity toward Rag A and B to suppress mTORC1 signaling 
(59,84). The five member GATOR2 complex, comprised of Mios (meiosis regulator for 
oocyte development), tryptophan-aspartic acid repeat-containing protein 24 (WDR24), 
WDR59, SEH1-like nucleoporin (Seh1L), and Sec13, inhibits GATOR1 (84,97). In the 





is relieved in the presence of arginine where CASTOR1 is proposed to directly engage 
arginine through its four tandem aspartate kinase chorismite mutase and TyrA (ACT) 
domains (59,86,98). In the absence of leucine Sestrin1/2 directly bind and inhibit 
GATOR2 (85), and leucine exclusively binds Sestrin1/2 to induce its dissociation from 
GATOR2 (99-101). 
KICSTOR, a four member complex consisting of ITFG2, KPTN, C12ORF66, and 
SZT2, localizes GATOR1 to the lysosome, enabling it to suppress mTORC1 in the 
absence of amino acids by exerting its GTPase activating protein (GAP) function toward 
the Rag GTPases and GATOR2 (59,102). Also, the heterodimeric FLCN-FNIP1 
complex, comprised of folliculin (FLCN) and FLCN-interacting protein 1 (FNIP1), 
translocates to the lysosome in the absence of amino acids, where it exerts GAP activity 
toward Rag C and D to maintain them in the active GDP-bound state, and dissociates 
from the lysosome in the presence of amino acids (59,103). This highlights the 
eloquently coordinated mechanisms underlying nutrient sensing by mTORC1. Both 
amino acid induced recruitment of mTORC1 to the lysosome and growth factor-
mediated phosphorylation and dislocation of TSC from the lysosome synergize, 
culminating in the full activation of mTORC1. Therefore, amino acid and growth factor 
signaling represent the best characterized activating mechanisms for mTORC1.  
mTORC1 is a well-established master regulator of cell growth (characterized by a 
cell autonomous increase in size and mass). Cell growth requires amenable amounts of 
lipids, nucleotides, and amino acids, and growth conducive signals induce mTORC1, 





functions as a metabolic rheostat by dually promoting anabolic programs and 
suppressing catabolic processes. Pro-growth conditions (i.e. sufficient levels of 
nutrients, growth factors, and energy) activate mTORC1, which promotes cell cycle 
progression (proliferation) and drives anabolic metabolism (12,57,60,104). Thus, 
mTORC1 is known as the master regulator of cell growth and an anabolic kinase.  
mTORC1 promotes cell growth by increasing protein synthesis through direct 
phosphorylation of two key substrates, p70 S6K1 on T389 and eukaryotic initiation 
factor 4E binding protein 1 (4EBP1) (on multiple sites including T37, T46, S65, and T70) 
(105-109). S6K1 phosphorylates elongation initiation factor (eIF) 4B to drive formation 
of the eIF4F complex, which associates with the 5’ cap of mRNA transcripts to drive 
their translation (12,110). Also, mTORC1-mediated phosphorylation of 4EBP1 induces 
its dissociation from eIF4E and also drives eIF4F complex assembly (12,105). Thus, 
mTORC1 promotes translation of 5’ cap-dependent mRNA, with a particular preference 
for transcripts harboring 5’ pyrimidine rich TOP-motifs, which encode for ribosomes and 
other essential translation machinery (12,57,111).  
mTORC1 also supports anabolic processes such as nucleotide and lipid 
synthesis, while it coordinately suppresses catabolic processes such as autophagy. 
mTORC1-mediated phosphorylation of Lipin 1, an inhibitor of the sterol response 
element binding protein (SREBP) transcription factors, effectively sequesters it in the 
cytoplasm, and S6K1-mediated phosphorylation of the SREBPs, both drive the 
synthesis of fatty acids, cholesterol, and lipids for membrane formation (12,112). 





energy production during cellular stress. Thus, mTORC1 also promotes the 
mitochondrial-associated tetrahydrofolate cycle through activation of methylene 
tetrahydrofolate dehydrogenase 2 (MTHFD2), which increases synthesis of one carbon 
intermediates for purine synthesis (57,113). S6K1-mediated phosphorylation of 
carbamoyl phosphate synthetase (CAD) on S1859 promotes the rate-limiting step of 
pyrimidine biosynthesis (57,114,115). Autophagy is a survival mechanism employed by 
cells to maintain homeostasis through the breakdown and recycling of old/damaged 
organelles and other macromolecules into their monomeric constituents. mTORC1 
suppresses autophagy by phosphorylating unc-51-like autophagy activating kinase 1 
(ULK1) on S757, thus preventing assembly of the autophagy-initiating complex 
comprised of ULK1, ATG101, ATG13, and FIP2000 (116,117). mTORC1 co-localization 
with the transcription factor EB (TFEB) at the lysosome enables mTORC1 to 
phosphorylate TFEB on S211, impeding its nuclear translocation and ability to drive 
expression of genes needed for autophagosomal and lysosomal biogenesis (118-120).  
Aberrant mTORC1 activation is a common feature of cancer and metabolic 
diseases. As such, mTORC1 is tightly regulated such that it is only activated in the 
presence of sufficient energy, pro-growth signals, and low stress. AMP activated protein 
kinase (AMPK) is a key sensor of cellular energy stress. A couple of indicators of 
energetic stress are deficient glucose levels and the accumulation of AMP in cells, both 
of which are sensed by AMPK via allosteric binding of AMP (121). Once activated, 
AMPK directly phosphorylates Raptor as well as TSC2 (to activate it) to inhibit mTORC1 





(REDD1) also coordinate to sense deficient oxygen levels and inhibit mTORC1 
signaling, also via phosphorylation and activation of the TSC (12,124). These represent 
clear examples of how cells ensure mTORC1 only becomes active under favorable 
conditions.  
 
1.4 mTORC2: signaling pathways, substrates, and cellular functions 
Growth factors, largely via the insulin/insulin-like growth factor (IGF)/PI3K 
pathway, activate mTORC2, which promotes cell survival and proliferation and 
modulates cellular metabolism (11,27,29,30). One group recently delineated interesting 
mechanistic detail underlying mTORC2’s involvement in the regulation of cell migration 
downstream of G-protein coupled receptor activation by chemoattractants in 
Dictyostelium discoideum (125,126). Intriguingly, and in contrast to accepted dogma 
that GDP-bound G-proteins possess very low activity and downstream activating 
potential relative to GTP-bound G-proteins, GDP-bound RacE was shown to interact 
with mTORC2 and promote mTORC2 signaling to Akt, which facilitated directional 
migration toward the chemoattractant cyclic adenosine monophosphate (cAMP) (125). 
Importantly, GTP-RacE was shown to antagonize RacE-GDP-mediated activation of 
mTORC2 (126). Specifically, in response to cAMP glycogen synthase kinase 3 (GSK-
3)-mediated phosphorylation of RacE-GDP on S192 promoted the assimilation of 
trimolecular complex comprised of RacE-GDP, RasC-GTP, and mTORC2, which 





migration toward cAMP (125,126). These studies highlight a key role for mTORC2 in 
Rho- and Ras-mediated directional cell migration.  
Through association with ribosomes, mTORC2 also catalyzes the co-
translational phosphorylation of Akt on its C-terminal turn motif on T450 as it threads off 
of the ribosome, which is essential for Akt stability, as it effectively positions the C-tail 
proximal to the kinase domain the (127-130). Recently, AMPK was shown to directly 
activate mTORC2 to promote cell survival during acute energetic stress (43). mTORC2 
directly phosphorylates members of the AGC kinase family to exert its cellular functions, 
the best known being Akt/PKB (30). mTORC2 is the prominent kinase for Akt S473 both 
in intact cells and in vivo, and phosphorylation of Akt on S473 boosts its kinase activity 
to a relative maximum level, while also conferring substrate specificity (12,131). 
mTORC2 also phosphorylates several conventional protein kinase C isoforms, including 
protein kinase C alpha (PKCa) on its turn motif on T638 and hydrophobic motif on 
S657, and PKCbII on its turn motif on T641 and hydrophobic motif on S660 
(11,128,129). Similar to mTORC2-mediated phosphorylation of Akt, phosphorylation of 
these sites seems to stabilize PKC isoforms.  mTORC2 also employs the partner 
protein Protor to phosphorylate the AGC member, serum and glucocorticoid-induced 
kinase 1 (SGK1) on its hydrophobic motif on S422, which is required for SGK1 
phosphorylation of downstream substrates (132,133). Unlike the case for Akt and 






While growth factors activate mTORC2, much less is known about how additional 
stimuli and associated signaling intermediates regulate and converge on mTORC2. 
However, through activation of AGC family kinases, mTORC2 regulates a plethora of 
cellular functions, including cell survival and proliferation, metabolism, and actin 
cytoskeletal organization associated with cell migration (12). Interestingly, mTORC1 
also regulates mTORC2 through a negative feedback loop. mTORC1-mediated 
phosphorylation of Grb10 enhances its inhibitory effect on insulin/PI3K signaling, and 
S6K1-mediated phosphorylation of IRS-1 induces its degradation (134,135). Both of 
these mechanisms effectively dampen PI3K flux to mTORC2 and Akt. 
 
1.5 Phosphorylation of mTOR and mTOR complex partner proteins  
 Phosphopeptide mapping and mass spectrometry based phosphoproteomic 
approaches have led to the identification of a swath of phosphorylation sites on mTOR 
and mTOR interacting partner proteins, Raptor, Rictor, and mSin1, most of which 
remain uncharacterized. In the case of mTOR, the direct mTORC1 substrate S6K1 was 
identified as a direct mTOR S2448 and T2446 kinase via a feedback mechanism with 
no known function (Fig 1.1) (39,40). Also, shortly after initial identification of the mTOR 
S2481 autophosphorylation site (41), Soliman et al demonstrated that this site 
accurately monitors both mTOR and mTOR complex specific catalytic activity in cells, 
as S2481 autophosphorylation increased in response to mTOR-activating stimuli (i.e. 
insulin and amino acids) and is reduced upon withdrawal of such stimuli (Fig 1.1) (42). 





mTORC1 and 2 signaling depending on the cellular context. mTOR S1261 was recently 
identified as a direct AMPK substrate that is phosphorylated in response to acute 
energetic stress, which increases mTORC2 activity and signaling to drive a pro-survival 
phenotype (Fig 1.1) (43). Finally, through an in vitro kinome screen of 300 human 
kinases, mTOR S2159 was identified as a novel TBK1 substrate, and in response to 
EGF and TBK1-activating innate immune agonists (i.e. poly (I:C) and LPS), TBK1-
mediated phosphorylation of mTOR S2159 promoted mTORC1 signaling and innate 
immune function (Fig 1.1) (44).   
 In the case of Raptor, the Ras/Raf/MAPK pathway was shown to promote multi-
site phosphorylation of Raptor (45,46). Indeed, p90 ribosomal S6 kinase 1 (p90 RSK1) 
and p90 RSK2 were demonstrated to phosphorylate Raptor following activation of 
MAPK kinase signaling, and through classic IP-MS, S719, S721, and S722 were 
identified as the prominent RSK1 and 2 substrates (Fig 1.3) (45). Importantly, Raptor 
phosphorylation of all three sites was required for MAPK kinase agonists to increase 
mTORC1 catalytic activity (45). Similarly, ERK2 was found to interact with Raptor, and 
ERK1/2 phosphorylated Raptor on proline-directed sites S8, S696, and S863, which 
promoted mTORC1 kinase activity in response to Ras/MAPK agonists (Fig 1.3) (46).    
 Another study identified mTOR itself as a kinase for both Raptor S859 and S863, 
but only Raptor P-S863 was found to contribute appreciably to increasing mTORC1 
kinase activity and signaling in response to insulin-mediated activation of the 
PI3K/TSC/Rheb axis (Fig 1.3) (47). Through IP-MS Foster et al identified six 





the above-mentioned sites (48). Raptor S863, in particular, was shown to function as a 
critical nexus between diverse pro-growth agonists (i.e. insulin, amino acids, and EGF) 
and mTORC1 activation, and Raptor S863 phosphorylation was a required prerequisite 
for subsequent phosphorylation on S855 and S859 (Fig 1.3) (48). Also, while mutation 
of S863 to alanine modestly reduced mTORC1 intrinsic catalytic activity, mutation of all 
six sites to alanine markedly reduced insulin-stimulated mTORC1 catalytic activity in 
vitro (48). Importantly, the sensitivity of growth factor and nutrient induced Raptor P-
S863 to rapamycin indicates that mTOR within mTORC1 is the Raptor S863 kinase in 
this cellular context. Thus, while all six of the Raptor phosphorylation sites appear to be 
positive regulators of mTORC1 under pro-growth conditions, it remains possible that a 
subset of them cooperate with additional uncharacterized or unidentified 
phosphorylation sites to negatively regulate mTORC1 in different cellular contexts.  
 In support of this notion, another study demonstrated that Raptor S863 
phosphorylation participates in a mechanism to suppress mTORC1 signaling in 
response to hyperosmotic and oxidative stress (Fig 1.3). Specifically, Nemo-like kinase 
(NLK)-mediated phosphorylation of Raptor S863 impeded mTORC1 recruitment to the 
lysosome by disrupting Raptor’s interaction with the Rag-GTPase (49). Also, it was 
demonstrated that Raptor S877 phosphorylation by TBK1 occurs in response to cellular 
stimulation with TBK1-activating innate immune agonists (i.e. LPS) to attenuate 
mTORC1 catalytic activity (Fig 1.3) (50). In the context of energetic stress, the AMP 
activated protein kinase (AMPK), in a manner dependent on the presence of its direct 





resulting in binding of the regulatory protein, 14-3-3, which allosterically attenuates 
mTORC1 intrinsic kinase activity and concomitantly arrests cells in G1/S phase of the 
cycle (Fig 1.3) (51). Note that a commonality among these studies is that 
phosphorylation of Raptor on these sites does not affect the critical mTOR-Raptor 
interaction.  
 Out of the 21 total Rictor phosphorylation sites originally identified by Dibble et al 
using LC-MS, Rictor T1135 was identified and characterized as a mTORC2 inhibitory 
site targeted by mTORC1 (52,53). Specifically, in response to growth factors, S6K1 
phosphorylated Rictor on T1135 to inhibit mTORC2 signaling exclusively to Akt S473, 
concomitant with impaired cell proliferation, without any effects on mTORC2 complex 
integrity or intrinsic catalytic activity (Fig 1.4) (52,53). Another group demonstrated that 
oncogenic Ras expression decoupled Rictor T1135 phosphorylation from IGF-1 
regulation, rendering it constitutive (54). Intriguingly, IGF-1-stimulated Rictor T1135 
phosphorylation was rapamycin and mTOR-dependent, invoking either mTOR, as part 
of mTORC2, or mTORC1 in modulating Rictor phosphorylation (54). Interestingly, but 
contrary to Julien et al and Dibble et al, no discernable increase in growth factor 
stimulated Akt P-S473 was observed, leaving the definitive function of Rictor T1135 an 
unresolved enigma (54). Collectively, this suggests that, rather than negatively 
regulating mTORC2 signaling to Akt S473, as reported by Julien et al and Dibble et al, 
Rictor T1135 phosphorylation exerts an unknown regulatory role, perhaps on other 
mTORC2 substrates or independently of mTORC2, that is possibly dependent on 





pharmacological inhibitor approaches to invoke S6K1 as a Rictor T1135 kinase, but 
Rictor T1135 phosphorylation has no effect on growth factor stimulated mTORC2 
signaling (55). Also, S6K1-mediated Rictor phosphorylation promoted binding of a 
regulatory protein 14-3-3 (55). Thus, while Rictor T1135 appears to serve as an 
inhibitory site, the differences among the studies highlighted above underscores the 
importance of future work aimed at characterizing the remaining Rictor phosphorylation 
sites. 
 Liu et al demonstrated that, in response to growth factors (i.e. EGF, PDGF, and 
IGF-1), S6K1 phosphorylated the mTORC2 partner protein mSIn1 on T86 and T398, 
effectively inducing its dissociation from the mTORC2 complex and severely attenuating 
mTORC2 intrinsic catalytic activity and signaling (Fig 1.5) (56). mSin1 phosphorylation 
at both sites also correlated with impaired mTORC2 engagement of Akt (56). 
Importantly, interrogation of a neighboring mutation (R81T) in mSin1 identified in an 
ovarian patient, revealed that phosphorylation of this site was required for T38 
phosphorylation in response to oncogenic growth factor receptor signaling, which 
correlated with increased FOXO3-mediated cell survival in response to the 
chemotherapeutic agents cisplatin and etoposide and tumor progression in vivo (56). 
Overall, while several of the above-mentioned phosphorylation sites have been linked to 
important functional outcomes, a largess of them remains uncharacterized or poorly 
characterized, underscoring how minimal our knowledge remains regarding the function 







1.6  Physiological functions of mTORC1 and mTORC2  
 The ability of mammals to appropriately regulate diet-induced fluctuations in 
circulating nutrients represents an evolutionary adaptation critical for both immediate 
post-natal and adult survival. Conveniently, mTOR orchestrates essential crosstalk 
between key metabolic target tissues (i.e. liver, skeletal muscle, and adipose tissue), 
primarily by sensing the post-prandial secretion of the hormone insulin from the 
pancreas, as well as nutrients (i.e. glucose and amino acids), inflammatory cytokines, 
and growth factors. Thus, mTOR signaling is critical for maintaining whole-body blood 
glucose homeostasis and lipid metabolism through both mTORC1 and mTORC2. The 
important roles of mTOR in metabolic homeostasis is supported by observations made 
from genetic mouse models.  
 Evidence that mTORC1 function is important for glucose homeostasis and insulin 
sensitivity includes the observation that mice harboring a constitutively active allele of 
Rag A die shortly after birth due to their inability to maintain blood glucose at amenable 
levels following perinatal fasting (136). Hyperactive mTORC1 signaling (via constitutive 
Rag A) also induces lethal hypoglycemia in mice, which was linked to impaired 
activation of autophagy in the liver to yield amino acids for de novo glucose production 
(136). Also, constitutive mTORC1 activation (via TSC2 knockout) in pancreatic beta 
cells long-term results in reduced beta cell size, insulin secretion, and glucose 
intolerance (137).  Genetic deletion of Raptor in adipose causes lipodystrophy, 





features compatible with triglyceride storage (138,139). This is exacerbated in mice 
administered a high-fat diet (HFD), and consequently, these mice develop metabolic 
defects including hepatomegaly (enlarged liver), hepatic steatosis (lipid accumulation in 
the liver), insulin resistance, and inflammation (139,140). Interestingly, however, these 
mice also display normal blood glucose levels and resistance to a HDF-induced 
increase in body mass. Adipocytes devoid of insulin receptor phenocopied mice lacking 
Raptor in adipocytes, invoking the insulin/IGF-1/PI3K/Akt pathway as a critical upstream 
mediator of mTORC1-dependent adipocyte maintenance (140).  
 Not surprisingly, mTORC2 is also crucial for maintenance of glucose 
homeostasis. Indeed, genetic deletion of Rictor in adipose impairs glucose uptake by 
adipocytes, increases lipolysis concomitant with reduced de novo lipogenesis, reduced 
adiposity, and promotes insulin resistance (140,141). While slightly less severe, these 
mice also exhibit hepatomegaly and steatosis, yet they are resistant to HFD-induced 
weight gain and exhibit normal adipocyte morphology (140,141). Collectively, these in 
vivo studies highlight a crucial role for mTORC1 and mTORC2 in control of lipid and 
glucose metabolism as well as whole body glucose tolerance and insulin sensitivity.  
Given the plethora of cellular processes controlled by mTORC1 and mTORC2, it 
is not surprising that aberrant activity of both complexes is implicated in cancer initiation 
and progression. Interestingly however, mutations in mTOR itself are rare; rather it’s the 
effect of collective mutations in components of upstream growth-promoting signaling 
pathways, most notably Ras/Raf/MAPK and PI3K/Akt, that lead to constitutive mTOR 





percent of human cancers (142). Constitutive mTORC1 activation, as a consequence of 
mutations in amino acid sensing pathway components, has been observed in some 
cancers. Specifically, mutations in the GATOR1 complex and the Rag C GTPase have 
been identified in the brain cancer glioblastoma and follicular lymphoma, respectively 
(97,143). It is suggested that these mutations confer a competitive advantage on cancer 
cells by enabling them to sustain high levels of proliferation under nutrient poor 
conditions (57). Mutations in Ras, Raf, the p110 catalytic subunit of PI3K, PTEN, and 
mTOR exist in a slew of different cancer types ranging from pancreatic to renal (12). 
mTORC2 is also implicated in tumorigenesis, as evidenced by the fact that Pten 
null prostate cancer cells lacking Rictor fail to form tumors following subcutaneous 
injection and successful Pten-induced transformation of normal prostate epithelium 
requires Rictor (144). mTORC2 has also recently been identified as a direct 
downstream effector of oncogenic Ras (145). mTORC2 preferentially interacts with 
oncogenic Ras over wild type Ras, and this interaction promotes a proliferative gene 
expression profile and tumor oncogenic Ras-driven tumor growth in vivo (146). 
mTORC2 also functions critically in melanoma cancer, as increased Rictor expression 
in melanoma tumor cells was found to promote Akt activation and tumor cell migration 
to, and metastasis of, the liver in response to signals excreted from hepatic stellate cells 
(147). Functional mTORC2 also promotes HER2-positive breast cancer migration and 
metastasis (148). 
Modulation of mTOR, and more specifically mTORC1, activity has been shown to 





homeostasis in a way that adversely affects physiological fitness, leading to a gradual 
decline in health span and longevity (57,149). mTOR’s multifaceted role in metabolic 
regulation renders it an attractive therapeutic target for improving age-related metabolic 
decline and reduced lifespan, as evidenced by the fact that reduced dietary caloric 
consumption reduces mTORC1 activity while extending lifespan (57,149). Indeed, one 
group demonstrated that genetic ablation of S6K1 increased lifespan, while curbing 
insulin resistance and immune and muscle decline (150). Importantly, S6K1 loss 
produced a transcriptional signature similar to one resulting from dietary restriction 
(150).  
Also, reduced mTOR expression significantly increased lifespan in 
Caenorhabditis elegans, and mutations in the C. elegans gene encoding Raptor (daf-
15) extended lifespan by decoupling mTORC1 activation from the insulin/IGF-1 pathway 
(151,152). Also, in C. elegans rapamycin or genetic perturbation of mTOR induced 
transcriptional upregulation of stress response genes mediated by the transcription 
factors SKN-1/Nrf and DAF-16/FoxO, while also extending lifespan (153). Also, 
administration of rapamycin to late-age mice curtailed the effects of aging to extend life 
span (154). Moreover, rapamycin rendered fruit flies resistant to starvation-induced 
stress while increasing longevity, which correlated with reduced protein translation and 
increased autophagy (155). Rapamycin administration to yeast in stationary phase 
improved longevity, in part by driving a stress protective transcriptional program 
orchestrated by the transcription factor Msn2 (156). The fact that mTORC1 inhibition 





cellular changes that incur with ageing supports the proposition of targeting mTOR to 
extend lifespan.  
Constitutive mTORC1 activity drives the high energy taxing process of protein 
synthesis, which likely consumes cellular energy needed for maintenance and 
protective mechanisms to mitigate ageing. This is supported by that fact that 
suppressing protein synthesis extends lifespan (157). Thus, mTORC1 inhibition shifts 
the cellular metabolic program toward a catabolic state, which increases autophagy, 
forcing the cell to breakdown and recycle old/damaged organelles for energy and 
macromolecular synthesis rather than through constant utilization of diet-obtained 
nutrients. Moreover, remaining in a net catabolic state indirectly reduces the 
accumulation of toxic metabolic by-products associated with heightened anabolism, 
which inadvertently damage existing organelles. Therefore, aged cells likely benefit from 
a slight net catabolic rather than anabolic program. Indeed, mice with increased basal 
autophagy conferred by mutational disruption of the association between beclin 1 and 
its negative regulator BCL2, exhibited increased longevity and protection against age-
related pathological alterations that compromise kidney and heart function (158). 
Interestingly, mTORC1 inhibition depends on functional autophagy machinery to 
produce desired anti-ageing benefits, as both the loss of essential autophagy genes and 
reduced mTORC1 activity fail to recapitulate the improved lifespan benefits that occur 
with dietary restriction (159,160).  
Finally, mTOR also has roles in neurophysiology and neurodevelopment, 





adverse outcomes, namely stark decreases in neuron autonomous growth and 
proliferation (contributors to microcephaly) and differentiation (57). Raptor knockout in 
the central nervous system progenitor cells results in the onset of microcephaly at 
approximately E17.5 due to an overall abbreviated cell cycle and apoptosis, as well as 
acute postnatal death (161). Rictor ablation in both the entire central nervous system 
and exclusively in Purkinje cells also resulted in decreased brain size attributed to a cell 
autonomous reduction in neuronal growth rather than increased cell death or decreased 
proliferation (162). Also, Rictor loss disrupted proper cerebellar morphology and folding 
and the extension of dendrite processes (57,162).  
Constitutive mTOR activation, largely a consequence of mutations that render 
essential upstream mTOR negative regulators inactive, also contributes to 
neurophysiological diseases (57,163). These diseases typically exhibit abnormal focal 
growths, an overall enlarged brain, and tumor growths in critical regions that can cause 
epileptic seizures. Indeed, inactivating mutations in NPRL2 and NPRL3, constituents of 
the GATOR1 complex which inhibits mTORC1 in response to amino acid starvation, 
correlated with the occurrence of cortex-specific focal dysplasia and resulting epileptic 
seizures (164). Also, conditional knockout of DEPDC5 (another GATOR 1 component) 
in neurons results in increased neuron size and focal dysplasia specifically within the 
cortex, concomitant with constitutive mTORC1 signaling, and motor abnormalities and 
spontaneous seizures (165). The best studied neuropathological disease is TSC 
syndrome, where inactivating mutations in either TSC1 or TSC2 results in increased 





brain, and in some cases, epileptic seizures (57). However, administration of rapamycin 
to mice harboring TSC1 mutations attenuates associated seizures, suggesting that 
mTORC1 might be an efficacious therapeutic target for ameliorating neuropathological 
diseases driven my aberrantly high mTORC1 activity (166). 
Unfortunately, minimal knowledge exists regarding the function of mTOR in the 
postnatal normal brain. However, activation of mTORC1 through genetic ablation of the 
negative regulator PTEN in retinal ganglion cells robustly promoted axon repair 
following artificial injury (167). Also, through PI3K activation, brain-derived neurotrophic 
factor (BDNF), a neurotrophin growth factor that promotes neuronal growth and 
differentiation, promotes localized protein synthesis within axons to enhance their 
migration and repair following injury (57,168,169). Lastly, several studies demonstrate 
that sufficient levels of mTOR signaling may aid in thwarting cognitive disorders such as 
autism spectrum disorder. Indeed, increased mTORC1-mediated localized protein 
synthesis within axons has been shown to correlate with autism-like behaviors in mice 
(170,171), whereas activation of autophagy through mTORC1 inhibition was shown to 
ameliorate the effects of autism spectrum disorder (172). These intriguing reports 
highlight the importance of future worked aimed at delineating the mechanisms through 
which mTOR contributes to brain development and neuropathological abnormalities 







1.7  mTORC2: the major physiological Akt-S473 kinase 
 Akt, also known as protein kinase B (PKB), is a member of the AGC (cAMP 
dependent, cGMP dependent, protein kinase C) family of serine/threonine kinases, and 
it exists in three isoforms in mammals: Akt1, Akt2, and Akt3 (173). All three isoforms 
possess the following structural elements: a central kinase domain flanked by an N-
terminal pleckstrin homology (PH) domain and a C-terminal hydrophobic motif (173). 
Through engagement of various effectors, AGC kinases, including Akt, regulate multiple 
cellular processes downstream of receptor tyrosine kinases, including cell growth, 
proliferation, and survival, differentiation, and apoptosis (173,174). Phosphorylation of 
Akt on its activation loop site (T308) is indispensable for its activation (175). Although 
recent groups have reported additional Akt-T308 kinases, PDK1 remains the accepted 
prominent Akt-T308 kinase in intact cells and in vivo (176-178). PDK1 also 
phosphorylates the conserved activation loop of several additional AGC kinases 
including p70 S6K1, p90 ribosomal S6K1 (RSK), and serum and glucocorticoid 
regulated kinase (SGK) (174). PDK1 regulation is governed by 3 elements: subcellular 
localization, conformational changes, phosphorylation (174). In response to growth 
factors (i.e. insulin/IGF-1) PDK1 is recruited, via its C-terminal PH domain, to PIP3 
decorated membrane regions. PH engagement of PIP3 induces a conformational 
change that relieves its autoinhibitory action on PDK1, allowing PDK1 to engage and 
phosphorylate substrates. PDK1 also requires trans-autophosphorylation on S241 in 
humans (S244 in mice) for growth factor activation. These regulatory mechanisms 





While PDK1-mediated phosphorylation of Akt-T308 is unequivocally required for 
Akt activation, phosphorylation of Akt within its hydrophobic motif on S473 is now 
appreciated as contributing profoundly to maximum Akt activity, stability of the active 
conformation, and dictating substrate preference (174). X-ray crystals of inactive and 
active Akt were seminal for elucidating the functional role of Akt-S473 phosphorylation 
(179,180). In the crystalized unactive Akt, the activation loop assumes a disordered 
configuration and sterically obscures the active site to restrict ATP and substrate access 
(174,180). Conversely, crystalized active Akt assumes a starkly different configuration in 
which Akt-S473 phosphorylation permits the hydrophobic motif to interact with the N-
terminal region of the kinase domain (174,179). This configuration not only represents a 
more stable conformation, but it also fully exposes the active site, effectively expanding 
the repertoire of substrates that Akt can accommodate (174,179). While mTORC2 
represents the major kinase for Akt-S473 in cells and in vivo (30), approximately ten 
additional Akt-S473 kinases have been proposed (discussed below). 
Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK 2 or 
M2K), activated in response to various cellular stress (i.e. heat shock), was shown to 
phosphorylate Akt-S473 in vitro, and a reduction in Akt-S473 phosphorylation was 
observed in neutrophils harboring an antagonizing M2K peptide (181,182). However, 
suppression of M2K activity in fibroblasts left insulin/IG-1- and stress-induced Akt-S473 
unperturbed, suggesting that M2K may phosphorylate Akt-S473 in vitro but not under 
normal physiological conditions (183). Integrin-linked kinase (ILK) was also initially 





recombinant ILK phosphorylates recombinant GST-Akt, as well as experiments 
employing genetic knockdown/knockout of ILK and expression of kinase dead alleles of 
ILK, all of which demonstrated a reduction in Akt-S473 phosphorylation in cells 
(174,184). However, follow up studies from other groups failed to recapitulate ILK-
mediated phosphorylation of Akt in vitro, and genetic ablation of ILK in fibroblasts or 
expression of a kinase dead ILK allele left insulin-stimulated Akt-S473 phosphorylation 
unperturbed (174,185,186). Evidence for the involvement of p38 MAPK in Akt-S473 
phosphorylation exists from approaches utilizing pharmacological inhibition of p38 
MAPK (with SB-203580) or expression of wild type or dominant negative p38M MAPK 
alleles or constitutively active alleles of the p38 MAPK upstream kinase MKK6 (174). 
Genetic or pharmacological inhibition of p38 MAPK reduced Akt-S473 phosphorylation 
in response to PIP3 (in neutrophils), PDGF, and EGF, but not insulin, and during muscle 
tissue development (181,187,188). Also, a constitutively active MKK6 allele drives Akt-
S473 phosphorylation (174). Conversely, cellular stress (i.e. reactive oxygen species) 
and insulin have also been shown to promote Akt-S473 phosphorylation independently 
of p38 MAPK (174,183,187). 
The protein kinase C (PKC) isoform PKCa was shown bind IGF-1-generated 
PIP3 on the plasma membrane and promote IGF-1-stimulated Akt-S473 phosphorylation 
in rat fat pad endothelial cells, and genetic perturbation of PKCa inhibited Akt-S473 
phosphorylation (174,189). Also, PKCa was shown to directly phosphorylate Akt-S473 
in vitro (189). Reconstitution of PKCbII devoid mast cells with PKCbII specifically was 





However, contrasting evidence challenges the postulation that conventional PKC 
isoforms (including PKCa and PKCbII) increase Akt S473 phosphorylation in vivo, as 
these isoforms do not require PI3K for localization to membrane regions decorated with 
phospholipase Cg1/2-generated diacylglycerol, and PKC’s generally recognize a basic 
consensus sequence, which differs from the typical hydrophobic motif consensus 
sequence encompassing S473 (174,191,192). Despite the inability of PKCz to 
phosphorylate the Akt3 isoform on its hydrophobic motif (S472) in vitro, it did interact 
with and promote phosphorylation of Akt3 in cells (193). Evidence for NIMA-related 
kinase 6 (NEK6) as a putative Akt-S473 kinase is woefully scant, particularly 
considering that NEK6 is known to support cellular progression through mitosis in a 
kinase-dependent manner (174,194,195). The only evidence that supports a role for 
NEK6 in Akt S473 phosphorylation is that PI3K inhibition with wortmannin or L-294002 
marginally reduced NEK6 kinase activity (174,196).  
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), isolated from 
membranes displaying constitutively active Akt S473 kinase activity (186), was shown to 
phosphorylate Akt-S473 in vitro, and although genetic ablation of DNA-PKcs or PI3K 
inhibition significantly reduced Akt S473 phosphorylation, residual phosphorylation 
remained (197). However, this contrasts with canonical roles of DNA-PK in the repair of 
dsDNA breaks and DNA replication (174). Also, DNA-PK preferentially recognizes ST/Q 
consensus motifs rather than the typical hydrophobic motif consensus sequence, and 
DNA-PK primarily engages its substrates by binding to DNA (174). Ataxia telangiectasia 





increased Akt S473, and not T308, phosphorylation in intact cells, but not in vitro (198). 
Also, ATM-induced Akt S473 phosphorylation was blunted following genetic depletion of 
ATM or inhibition of PI3K (198). Recently, the non-canonical Ikb kinase-related kinases 
TBK1 and IKKe, best known for their role coordinating pathogen detection with initiation 
of the innate immune response, have also been identified as Akt S473 (and Akt T308) 
kinases (177,199). None of the abovementioned studies provide compelling evidence in 
support of any of these kinases as bona fide Akt-S473 kinases for a few reasons. A 
majority of the studies employed overexpression and/or in vitro kinase assays, which 
tend to promote non-physiological phosphorylation events due to dysregulated kinase 
and substrate localization or other regulatory mechanisms. In addition, the cellular or 
physiological contexts differed quite drastically between the studies, with some studies 
investigating growth factor-mediated activation of Akt and others looking in specific 
immune cells (i.e. neutrophils). It is possible that in unique cellular context that one or a 
few of these kinases might acquire the ability through perhaps a compensatory 
mechanism to phosphorylate Akt S473, but under normal physiological conditions it 
doesn’t appear to be the case. Thus, mTORC2 remains the physiologically relevant Akt-
S473 kinase in intact cells and in vivo (30). 
   
1.8  TBK1 and IKKe: identification, structure, and mechanisms of activation 
 The noncanonical IKK-related kinases, Tank-binding kinase 1 (TBK1), also 
known under the aliases TRAF2-associated kinase (T2K) and NF-kB-activating kinase 





distinctly from the canonical IKKs (i.e. IKKa and IKKb). TBK1 is a 729 residue 84 kD 
protein, and IKKe is 716 residues and 80 kD (200) (Fig 1.6). TBK1 was originally 
identified and cloned through its interaction with TANK (201,202), and IKKe was 
originally identified as a gene whose expression is induced following stimulation of 
macrophages with bacterial lipopolysaccharide (LPS) (203). TBK1 and IKKe share 49% 
identity and 64% similarity (202,204), and both harbor the following structural domains: 
a N-terminal kinase domain, a ubiquitin-like domain (ULD), a C-terminal leucine zipper 
(also known as the scaffold/dimerization domain (SDD)), and a C-terminal helix loop 
helix (HLH) (FIG) (204). While TBK1 enjoys ubiquitous expression across virtually all 
tissue types, IKKe expression is more restricted and includes peripheral blood 
lymphocytes and epithelial cells (204). The ULD of TBK1 and IKKe is crucial for their 
function in inducing the antiviral interferon response, and K63-linked polyubiqutination of 
lysines 30 and 401 within the ULD of TBK1 and IKKe and subsequent phosphorylation 
of both on serine 172 are both required for their activation (205). The SDD domain 
enables TBK1 and IKKe to homodimerize and form higher order oligomeric structures. 
Most of the cellular pool of TBK1 exists as stable homodimers, where contacts between 
the KD, ULD, and SDD culminates in a zipper-like backbone structure that effectively 
positions the kinase domains in directional opposition to each other (200). This is 
believed to be an inherent regulatory mechanism to discourage aberrant TBK1 
activation, which would likely contribute to pathological inflammation. Two mechanisms 
have been proposed to describe activation of TBK1. The first describes adaptor-





upstream kinase co-localizes to directly phosphorylate and activate TBK1 (206). The 
second also describes adaptor-mediated recruitment of TBK1 where instead, local high 
concentrations of TBK1 dimers enable proximal-mediated phosphorylation on S172, 
termed transautophosphorylation (207).   
 
1.9  Innate immunity: Roles for the noncanonical IKK kinases (TBK1 and IKKe) 
and NF-kb  
TBK1 and IKKe constitute key signaling nodes of the host’s first line of defense 
against pathogenic infections. The innate immune system comprises various types of 
pattern recognition receptors (PRR) that detect microbial-derived antigens, collectively 
known as pathogen associated molecular patterns (PAMPs) (200). PRRs that activate 
TBK1 and IKKe include the membrane associated Toll-like receptors (TLRs) and the 
cytosolic DNA sensing receptor cyclic GTP-ATP Synthetase (cGAS) (208-211). Ligand 
engagement of TLR-3 or TLR-4 specifically leads to the activation of TBK1 and IKKe 
TLR-3 resides primarily on endosomal membranes, and in certain cell types on the 
plasma membrane, whereas TLR-4 exclusively occupies the plasma membrane 
(209,212) (Fig 1.7) . TLR-3 recognizes viral dsRNA exposed during lysosomal 
degradation of viral particles and during viral genome replication, as well as the 
synthetic dsRNA mimetic, polyribinosinic polyribocytidylic acid (poly I:C). TLR-3 has 
also been shown to recognize a subset of ssRNA and dsDNA viruses (212-214).TLR-4 
recognizes lipopolysaccharide (LPS), a constituent of the outer membrane of gram-





homodimerize, which causes a conformational change in the cytoplasmic Toll-
Interleukin 1 receptor (TIR) domain, initiating the recruitment of key adaptors (210). Both 
TLR-3 and TLR-4 employ the adaptor TRIF, while TLR-4 also accommodates TRAM, to 
transduces their signals (210). TRIF and/or TRAM recruitment precedes recruitment of 
TBK1 and IKKe, where they are activated by transautophosphorylation on their 
activation loop site on serine 172 (Fig 1.7). TBK1 and IKKe then phosphorylate 
interferon regulatory factor (IRF) 3/7, which induces their homodimerization and nuclear 
translocation where they transcriptionally induce the interferon response (210,215) (Fig  
1.7).  
cGAS-cGAMP (cGMP AMP)-STING (stimulator of interferon genes) represents 
another conduit through which certain PAMPs activate TBK1 (211). cGAS is an 
intracellular receptor that senses and binds bacterial and viral derived dsDNA (211,216) 
This binding induces a conformational change that promotes cGAS oligomerization and 
activation, allowing it to catalyze the synthesis of cGAMP from ATP and GTP 
(211,217,218). cGAMP binds to ER-localized STING molecules, which induces STING 
dimerization and subsequent oligomerization as these complexes translocate to the 
perinuclear region (211,219). In route to the perinuclear regions TBK1 is recruited and 
activated via transautophosphorylation (211). TBK1 then phosphorylates and activates 
IRF-3/7 to promote the antiviral INFb response (211,215). It is important to note that 
TBK1 deletion in mice is embryonic lethal at E14.5 as a consequence of hepatic 
apoptosis and liver degeneration, underscoring the importance of TBK1 in both innate 





TBK1 function also participates in autophagy-mediated sequestering and 
clearance of invading bacteria from mammalian cells. Classic participation of TBK1 in 
autophagy involves its interaction with and phosphorylation of the cargo receptor 
optineurin through key adaptors, including NDP52 (221) (222). These general 
mechanisms link TBK1 to autophagosome maturation and the eventual autophagic 
elimination of pathogenic bacteria (222-224), as well as the selective recycling of 
old/damaged mitochondria (225,226). In response to poly (I:C) and viral infection, 
optineurin also recruited TBK1, in a K63 polyubiquitin-dependent manner, to the golgi 
apparatus to promote INF-b production (227). Additionally, interaction with the 
endosomal marker Rab8 promotes TBK1-mediated phosphorylation of the core 
autophagy adaptor p62/sequestosome on S403, which promotes the macrophage 
eradication of Mycobacterium tuberculosis (223). Also, adaptor-mediated recruitment of 
kinase-active TBK1, via the cargo receptor NDP52 and independently of optineurin, to 
the autophagy proteins WIPI2 and WIPI1 was found to be essential for TBK1 to thwart 
Salmonella typhimurium infection by impeding its replication (228).  
 The NF-kB pathway responds to a plethora of cellular stimuli (pro-inflammatory 
cytokines such as TNF-a and IL-1; DNA damage (i.e. dsDNA breaks); oxidative stress; 
and pathogenic constituents such as bacterial LPS) and responds through 
transcriptional regulation of a myriad of genes involved in innate and adaptive immunity, 
inflammation, cell survival and proliferation (202,229). The mammalian NF-kB family 
consists of five members: NF-kB1/p50 (obtained via proteolytic cleavage of the p105 





RelA/p65; and RelB (230). These proteins associate in a combinatorial fashion via their 
conserved Rel homology domain (RHD) to yield various NF-kB heterodimeric 
transcriptional activators (230). Importantly, the RHD also confers DNA binding 
capabilities and provides a contact interface for the NF-kB negative regulators, the 
inhibitor of kB (IkB) proteins (230). The RHD also harbors a nuclear localization signal 
(NLS) critical for NF-kB entry into the nucleus (202). 
The IkB proteins prevent aberrant NF-kB activation and ensure it is only activated 
when when appropriate. In the absence of NF-kB activating stimuli (i.e. TNF-a), through 
its stacked helical-rich ankyrin repeats, IkBa binds to NF-kB dimers to obscure their 
nuclear localization signal (NLS). This effectively impedes NF-kB function by 
sequestering it in the cytoplasm (202,230).  
Two pathways are known to activate NF-kB: the classical pathway and the 
alternative pathway. The classical pathway is governed by IKKb, a catalytic subunit of 
the trimolecular canonical IkB kinase (IKK) complex. The canonical IKK complex 
comprises another catalytic subunit, IKKa, and the regulatory subunit IKKg (also known 
as NF-kB essential modulator, NEMO) (202,231). Following cytokine stimulation, IKKb, 
as part of the IKK complex, phosphorylates IkBa on serine 32 and 36 (232), flagging it 
for recognition by the b-TrCP F-box component of the E3 ubiquitin ligase complex Skp-
1-Cullin-F-box (SCF), referred to as SCFbTrCP (233,234). SCFbTrCP then polyubiquitinates 
IkBa on lysine 21 and 22, which targets it for recognition and degradation by the 26S 
proteasome (202,234-237). IkBa degradation liberates NF-kB (RelA(p65):p50) dimers, 





target genes involved in proliferation (i.e. cyclin D1), apoptosis suppression (i.e. BCL-
XL), inflammation (i.e. the inflammatory enzyme, cyclooxygenase 2 (Cox-2), and the 
pro-inflammatory cytokine, IL-6) (229).   
The alternative pathway is uniquely governed by IKKa, where, rather than 
phosphorylating IkBs, it phosphorylates NF-kB2(p100) precursor (202). NF-kB2(p100) 
phosphorylation leads to recruitment of and polyubiquitination by the SCFbTrCP complex, 
which mediates proteasomal degradation of the C-terminal IkB region of NF-kB2(p100) 
(202,238). This yields the mature p52 form, which, as a dimer with RelB, translocates to 
the nucleus to exert its transcriptional activity (239). While IKKg is required for IKK 
complex integrity and NF-kB activation via the classical pathway, it is dispensable for 
NF-kB activation via the alternative pathway. Also, while not required for classical NF-
kB activation in response to pro-inflammatory cytokines, alternative NF-kB activation by 
IKKa in response to certain stimuli (i.e. receptor activator of NF-kB (RANK) ligand) and 
in certain cell types requires activation loop phosphorylation on serine 176 and 180 
(202,240-242).  
Constitutive NF-kB signaling can lead to pathological levels of inflammation. The 
adverse effects of constitutive NF-kB activity have been observed in mice genetically 
devoid of IkBa (IkBa-/-), which die approximately one week post-birth due to 
complications from an inflammatory skin condition (243). Therefore, regulatory 
mechanisms exist to shut down NF-kB signaling after it has exerted its functions. One 
example involves IkBa directly. IkBa is uniquely a transcriptional target of NF-kB. 





IkBa proteins, which enter the nucleus, bind to NF-kB to disrupt its association with IkB 
gene elements, and escort NF-kB back into the cytoplasm using its nuclear export 
sequence (230,244).  
 
1.10  Toll-like receptor (TLR) 3 and 4 
 The toll-like receptor family consists of 10 total functional members in humans 
(TLR 1-9) and 13 in mice (TLR 1-9 and 11-13; TLR-10 is non-functional) (208). TLRs 
recognize a diverse array of PAMPs that occur both intra- and extra-cellularly, including 
lipoproteins and bacterial/viral nucleic acid (ie ssRNA) (208). All TLRs harbor an N-
terminal leucine rich repeat (LRR)-containing ectodomain, a transmembrane domain, 
and a C-terminal Toll-interleukin1 receptor (TIR) domain (245,246). The ectodomain 
assumes a globular, horseshoe shape and is essential for TLR recognition of 
appropriate PAMPs (245). Following PAMP binding, TLRs associate with various 
adaptor molecules in a stimulus-specific manner to transduce signals downstream 
(208). These adaptors contain a Toll/Interleukin 1 receptor (TIR) domain, which enables 
them to interact with the TIR domains of TLR molecules (208). It is now appreciated that 
TLRs are co-translationally translocated into the endoplasmic reticulum (ER) and 
subsequently trafficked through the secretory pathway, where they undergo processing 
before being translocated to their appropriate membrane platform (208). Dysregulated 






The TLR family is bifurcated into two broad groups, one which resides on the 
plasma membrane and another which resides on internal membrane organelles. One of 
the earliest TLR’s to be discovered and characterized, TLR-4 traffics to the plasma 
membrane with the assistance of the required ER-resident proteins, PRAT4A, and the 
heat shock protein 90 (hsp90) family member gp96 (209,247).  where it forms a 
functional heterodimer with myeloid differentiation factor 2 (MD-2) (248,249). The six 
lipid chains of LPS intricately engage the TLR-4/MD-2 complex, with five of the lipid 
chains interacting strongly with the hydrophobic pocket of MD-2 and the remaining lipid 
chain bridging the complex by interacting with a phenylalanine residue on TLR-4 
(248,249). In addition to LPS, TLR-4 has been reported to recognize an envelope 
protein of murine mammary tumor viruses as well as fusion proteins of respiratory 
syncytial virus (208,250). Following LPS binding, TLR-4 recruits the adaptor molecules, 
TIRAP and myeloid differentiation factor 88 (MyD88) to activate MAPK signaling and 
initiate NF-kB-mediated pro-inflammatory cytokine production (208,212). MyD88 is 
critical for the recruitment of several key IL-1 receptor associated kinases (IRAKs): 
IRAK4, IRAK1, and IRAK2 (251,252). Upon activation of the IRAKs, TRAF6 is recruited 
where it catalyzes the K63-linked polyubiquitination of itself and IRAK1 (208,253). 
These polyubiquitin chains function to tether several proteins for proximal activation. 
The polyubiquitin chains of TRAF6 engage the kinase, TAK1, through the ubiquitin 
binding domain (UBD) its regulatory subunits TAB2 and TAB3, as well as the canonical 
IKK complex (a tri-molecular complex comprised of two catalytic subunits IKKa and 





proximal phosphorylation of IKKb by TAK1, which activates and primes NF-kB for pro-
inflammatory gene expression. 
TLR-4 also interacts with the adaptors Toll-IL-1-receptor domain-containing 
adaptor inducing interferon beta (TRIF) and TRIF-related adaptor molecule (TRAM) to 
transmit signals through both MyD88 and TRIF, culminating in NF-kB and interferon 
responses (254). Shortly after LPS binding and together with the co-receptor CD14 
(255), TLR-4 undergoes endocytosis, which vitiates the MyD88 interaction to permit 
TRIF and TRAM to bind and recruit and activate TBK1/ IKKe, which activates IRF3/7 
and the interferon response (208,212,256). Interestingly, TLR-4 represents the only TLR 
for which engagement by both MyD88 and TRIF/TRAM are required for a sufficient pro-
inflammatory cytokine response (208). This mechanism highlights the degree to which 
specific adaptors fine tune TLR-mediated innate immune responses.  
TLR-3 localizes to endosomal membranes where it recognizes viral-derived 
dsRNA, which arises either from viral degradation or exposure during viral genome 
replication (212). Evidence suggests that the ER-resident 12-membrane pass protein, 
UNC93B1, is involved in trafficking of TLR-3 to endosomes, because it directly binds the 
transmembrane domain of TLR-3 and a specific missense mutation in UNC93B1 
impairs TLR-3-mediated immune responses (257). TLR-3 Initial studies identified TLR-3 
by its ability to bind the synthetic viral dsRNA mimetic polyriboinosinic polyribocytidylic 
acid (poly I:C) (208). TLR-3 has also been shown to bind the dsRNA intermediate that 
occurs during the replication of ssRNA viruses as well as small interfering RNA (208). 





analysis of TLR-3 reveals a solenoid conformation with a horseshoe configuration 
(245,258). The characteristic LRR within the ectodomain contribute to the solenoid 
conformation, and several key asparagine residues provide stabilizing hydrogen 
bonding (258). The importance of TLR-3 function in coordinating the antiviral interferon 
response is underscored by the fact that humans lacking sufficient TLR-3 exhibit 
increased susceptibility to herpes simplex virus (HSV) infection, and mice lacking TLR-3 
die following infection with murine cytomegalovirus (213,259). 
TLR-3 is the only TLR member that does not employ MyD88, yet it is still able to 
activate NF-kB inflammatory gene expression and interferon beta production. TLR-3 
interacts with the adaptor TRIF via its TIR domain, and TRIF-mediated recruitment of 
the E3 ubiquitin ligases, TRAF6 or Pellino-1, RIP1, and TRADD, enables crosstalk with 
the MyD88 pathway via activation of TAK1, which activates the NF-kB axis (208). 
TRADD and Pellino-1 interaction with RIP1 seems to mediate K63-linked 
polyubiquitination of RIP1, which is essential for TLR-3-mediated NF-kB activation 
(260,261). TRIF-mediated recruitment of the adaptor TRAF3 contributes profoundly to 
the induction of interferon beta production. TRAF3 subsequently recruits TBK1 and 
IKKe leading to their phosphorylation on S172 and activation, and TBK1/ IKKe 
phosphorylate and activate IRF3, culminating in the transcriptional and translational up-
regulation of type 1 interferons. The fact that genetic ablation of TRAF3 curtails 
activation of TBK1 and IKKe activation underscores the importance of TRAF3 in 





Aberrant TLR signaling is implicated in pathophysiological conditions associated 
with chronic inflammation, including cancer and autoimmune disorders. Therefore, cells 
leverage multiple tiers of regulation to minimize this potential outcome. Numerous 
molecules have been identified as suppressors of both MyD88 and TRIF signaling. TAG 
(TRAM adaptor with Gold domain) negatively regulates TLR-4/TRIF-mediated IRF3 
activation by disrupting the TRIF/TRAM interaction at the TLR-4 cytoplasmic interface 
(262). The integrin CD11b seems to generally antagonize MyD88 and TRIF responses 
downstream of TLRs by promoting the ubiquitin-mediated degradation of both in 
coordination with the E3 ubiquitin ligase, Cbl-b (263). TRAF3-mediated proximal 
ubiquitination of TBK1 is required for TBK1 activation. The deubiquitinating enzyme A 
(DUBA) blunts type 1 interferon production by binding to and cleaving the polyubiquitin 
chains on TRAF3, effectively dislocating it from TBK1 to prevent TBK1 activation and 
type 1 interferon induction (264). The peptidyl prolyl isomerase Pin1 also negatively 
regulates type 1 interferon production by interacting with and promoting the proteasomal 
degradation of phosphorylated IRF3 and (265). Negative regulation of the NF-kB/MAPK 
inflammatory response is exemplified by the report that TRIM30a interacts with and 
promotes degradation of the ubiquitin-binding proteins, TAB2 and TAB3, which 
functions to bring TAK1 in proximity to the canonical IKK complex for NF-kB activation 
(266). Collectively, these reports highlight the importance of a regulatory check on TLR 







1.11 TBK1 and IKKe in oncogenesis 
Roles for TBK1 and IKKe in tumorigenesis have also recently been described. 
TBK1 and IKKe have also been implicated in the promotion of cancer cell survival and 
proliferation (267). IKKe functions as a breast cancer oncogene where, upon K63-linked 
polyubiquitination on lysines 30 and 401, orchestrated by the cIAP1/cIAP2/TRAF2 E3 
ubiquitin ligase complex, it synergizes in parallel with NF-kB pro-inflammatory signaling 
to exert its cellular transformation and oncogenic functions (268). IKKe gene 
amplifications and overexpression also exist in approximately 30 percent of breast 
cancers (269). Significant transcriptional and translational up-regulation of IKKe 
expression has been reported in glioma cancers, where functionally it seems to 
leverage the NF-kB-mediated production of the anti-apoptotic factor, Bcl-2, to promote 
glioma cancer cell survival (270). Interrogation of ovarian cancer patient samples 
revealed that IKKe expression was noticeably increased in metastatic samples relative 
to primary tumors samples, and IKKe seems to drive a cell motility and pro-inflammatory 
gene signature, which correlated with increased metastasis of a less aggressive ovarian 
cancer (271). IKKe is also critical for oncogenic Ras-driven pancreatic tumorigenesis 
and progression through its ability to activate the survival kinase, Akt, in a mTOR-
independent manner through activation of the Gli1 transcription factor (272). Indeed, 
IKKe expression is appreciably increased in patient pancreatic ductal adenocarcinoma 
samples (273). IKKe also promotes non-small cell lung tumorigenesis through an 





to increase its kinase activity and IKKe promotes pro-proliferative, growth, and survival 
pathways via activation of Akt and MAPK (274).  
Interestingly, elevated TBK1 expression has also been identified in ER-positive 
breast cancer, which correlates with resistance to the common treatment regimen 
tamoxifen, and specifically, TBK1-mediated phosphorylation of ERa on S305 was found 
to promote tamoxifen-resistance in these ERa positive breast cancers (275). TBK1 was 
also identified in an shRNA kinome screen as essential for HER2 positive breast cancer 
growth and proliferation, and pharmacological inhibition of TBK1 induced senescence 
through reduced canonical NF-kB signaling (276). TBK1 is also critical for the survival 
and proliferation of adult T-cell leukemias (ATL) driven by constitutive NF-kB activity, 
where TBK1 (and IKKe) promotes pro-growth/survival STAT3 signaling (277). TBK1 was 
recently identified in an siRNA screen as a critical factor that promotes the survival and 
proliferation of cancer cells harboring oncogenic KRas mutations, presumably through 
coordination with NF-kB antiapoptotic signaling (278). TBK1 (and IKKe) were also 
shown to promote oncogenic KRas-driven lung adenocarcinoma growth and survival in 
vivo through the activation of the chemokine chemokine ligand 5 (CCL5) and the 
cytokine IL-6 (279). TBK1 also suppresses apoptosis in MEFs transformed with 
oncogenic KRas through the exocyst complex (specifically exocyst member Sec5) and 
activation of the RalB GTPase (280). TBK1 also regulates autophagy to promote cancer 
cell survival and proliferation. Similar to its role in promoting autophagosome formation 
to eradicate invading bacteria, TBK1 selectively sequesters the autophagy cargo 





signaling and promote survival and proliferation of cancer cells harboring oncogenic 
KRas (223,281). Moreover, both TBK1 and IKKe have been shown to directly 
phosphorylate and activate the survival kinase Akt on T308 and S473 to support 
oncogenic transformation (177,199). Collectively, these studies demonstrate that TBK1 
and IKKe support oncogenesis through a plethora of mechanisms depending on the 
context and specific cancer type/subtype.  
 
1.12 TBK1 and IKKe in metabolism and metabolic diseases 
Several studies also report roles for TBK1 and IKKe in the regulation of 
metabolism as well as their implication in diet-induced metabolic diseases. TBK1 has 
been linked to insulin-mediated glucose homeostasis based on its ability to control 
glucose uptake in cells. Specifically, TBK1 promotes glucose uptake by regulating 
GLUT4 trafficking to the plasma membrane through engagement of the exocyst 
complex and phosphorylation of Exo84 (282). Initial reports demonstrated that global 
knockout of IKKe in mice confers protection against the untoward effects of diet-induced 
obesity, specifically by reducing chronic inflammation in adipose and liver, reducing lipid 
accumulation in the liver, and improving global insulin sensitivity (283). Similarly, an 
independent study demonstrated that administration of the TBK1/ IKKe inhibitor 
amlexanox to mice challenged with a high fat diet also improved insulin sensitivity and 
protected against weight gain, through increased calorie burning, and hepatic steatosis 
(284). Also, these studies reported elevated TBK1 and IKKe expression and activity in 





which strengthened the idea that TBK1/ IKKe might contribute to the metabolic defects 
incurred with diet-induced obesity (283,284). Unfortunately, it is difficult to discern the 
precise physiological role of IKKe (or TBK1) to diet-induced obesity via global knockout 
or administration of a pharmacological agent. Therefore, it remains unclear how exactly 
IKKe improved insulin sensitivity in these studies.  
Interestingly, the same group later discovered that knockout of TBK1 in 
adipocytes exacerbates inflammation, promotes insulin resistance, and disrupts glucose 
homeostasis (i.e. hyperglycemia) (285), instead supporting a physiological role for TBK1 
in ameliorating obesity-linked metabolic dysregulation by reducing inflammation and 
promoting whole body insulin sensitivity and glucose homeostasis. Intriguingly, these 
mice maintain normal body weight and fat biomass. Zhao proposes that TBK1 curbs the 
inflammation by inhibiting NF-kB pro-inflammatory signaling through phosphorylation-
mediated degradation of NF-kb inducing kinase (NIK) (285).  
Also, while whole body knockout of TBK1 ameliorated diet-induced obesity-
driven fatty liver, liver specific knockout of TBK1 actually exacerbated fatty liver, which 
was mechanistically explicated by TBK1’s function in the regulation of fatty acid b-
oxidation (286). Interestingly, TBK1’s role in circumventing lipid accumulation in the liver 
was attributed to its scaffolding function rather than its kinase activity. Specifically, 
inactive TBK1 sequestered acyl CoA synthetase long-chain family member 1 (ACSL1) 
in the mitochondria, effectively impeding its ability to translocate to the endoplasmic 
reticulum (ER) during fasting to produce acyl CoA that, upon esterification, yields fatty 





mitochondria to drive aberrant fatty acid b-oxidation in the ER, consequently leading to 
fatty acid build up in the liver (286). Recently, Reilly et al elucidated a mechanism to 
explain the metabolic benefits conferred upon high fat diet-induced obese mice by 
amlexanox, namely sustained long-term weight loss through increased energy 
expenditure and improved insulin sensitivity. Specifically, amlexanox promoted 
browning of white adipose by increasing fibroblast growth factor 21 (FGF21) expression 
specifically in adipocytes, and in an autocrine fashion, FGF12 induced the 
transcriptional upregulation of genes involved in white adipose browning, namely Ucp1 
and Dio2 (287). Importantly, amlexanox improved overall metabolic profiles of these 
obese mice in two key ways. First, by curbing fasting blood glucose levels through 
adipocyte-liver crosstalk, where amlexanox-induced secretion of IL-6 from adipocytes 
inhibited signal transducer and activator of transcription (STAT3) signaling in the liver to 
quell hepatic glucose production and secretion into the bloodstream. Second, and more 
long-term, the increased energy expenditure conferred on these mice by amlexanox 
also resulted in improved insulin sensitivity (287). This study mechanistically 
characterizes TBK1 and IKKe as reconcilers of high fat diet (HFD)-induced obese 
metabolic abnormalities, notably HFD-induced weight gain and insulin resistance. 
However, the exact role of inflammation in obesity-linked insulin resistance remains 
poorly understood. Nonetheless, these independent studies describe important roles for 
TBK1 (and IKKe) in integrating inflammatory and metabolic cues within metabolic target 






1.13 Introduction to dissertation research  
 Growth of eukaryotic organisms requires both cell autonomous and non-
autonomous coordination through the sensing of pro-growth cues. mTOR represents an 
evolutionarily conserved serine/threonine protein kinase that functions as a critical 
conduit between environmental cellular conditions and intracellular responses, aimed at 
maintaining homeostasis. mTOR exists as the core kinase of two multisubunit 
complexes known as mTOR complex 1 (mTORC1) and mTORC2. Known as the master 
regulator of cell growth, mTORC1 also mobilizes an anabolic cellular program to 
support cell growth and cell cycle progression. mTORC2 senses growth factors and 
energetic cellular stress and responds by promoting cell survival and proliferation 
through the survival kinase, Akt. The environmental cues and signaling 
mechanisms/intermediates governing mTORC1 remain far more extensively 
characterized than for mTORC2. Therefore, the research presented here contributes 
important mechanistic insight to the woefully minimal body of knowledge regarding 
upstream regulation of mTORC2. 
 Previous work from our lab identified mTOR serine 2159 as a site that promotes 
mTORC1 signaling (Figure 1.1) . Mutation of this site to a nonphosphorylatable alanine 
was found to reduce mTORC1 signaling (104). An in vitro kinome screen in search of 
the mTOR-S2159 kinase identified TBK1 and IKKe as strong candidates (44). Studying 
TBK1 regulation of mTOR revealed that TBK1 is essential for EGF to activate promote 
mTORC1 signaling. MEFs genetically lacking TBK1 displayed profoundly reduced EGF-





signaling. Importantly, wild type but not kinase dead TBK1 rescued EGF-stimulated 
mTORC1 signaling in TBK1 knockout MEFs. Notably, TBK1-mediated mTOR-S2159 
phosphorylation was found to contribute to canonical innate immune functions of TBK1. 
In response to the detection of pathogen-derived molecular features, TBK1 initiates the 
innate immune response by phosphorylating the transcription factors IRF-3/7 to induce 
their homodimerization and nuclear translocation, culminating in the production of IFN-
a/B (Figure 1.4). Indeed, mTORA/A primary bone marrow derived macrophages 
(BMDMs), isolated from mice genetically modified to bear mTOR-S2159 alanine 
substitutions at both mTOR alleles, exhibited impaired IRF-3 nuclear translocation and 
IFN-b production. This novel function for site-specific mTOR phosphorylation in innate 
immunity revealed that TBK1 crosstalk with mTOR also modulates key cellular 
processes.  
 While studying TBK1-mediated activation of mTORC1 we also observed reduced 
EGF-stimulated Akt P-S473 in MEFs devoid of TBK1, a key piece of preliminary data 
suggesting that TBK1 may also be important for EGF-stimulated mTORC2 signaling. 
The data here clearly demonstrate that TBK1 represents a novel direct upstream 
activator of mTORC2 and delineates the mechanistic details underlying TBK1 activation 
of mTORC2. Most importantly, results from this study provide targetable therapeutic 
options for diseases driven by aberrant TBK1 and mTORC2 activity such as cancer and 









Figure 1.1: mTOR domain structure. mTOR contains N-terminal tandem HEAT 
repeats, which mediate mTOR complex dimer formation via protein-protein interactions; 
a FAT domain; FKBP12 rapamycin binding domain (RBD) to which the rapamycin-
FKBP12 complex docks to inhibit mTORC1; a kinase domain; and a FATC domain. 
mTOR S1261 is phosphorylated by AMPK in response to acute energetic stress (43). 
mTOR S2159 is phosphorylated by TBK1, which promotes EGF stimulated mTORC1 
signaling and INFb production and IFR-3 nuclear translocation in response to innate 
immune agonists (44). mTOR S2448 is phosphorylated by S6K1 via a feedback 
mechanism with no known function (39). mTOR S2481 is an autophosphorylation site 







Figure 1.2: Activation of mTORC1 and mTORC2 by stimuli. EGF activates EGF 
receptor (EGFR) leading to phosphorylation of specific tyrosine residues on the 
intracellular cytoplasmic domain of the receptor. Growth factor receptor bound protein 2 
(Grb2) and SOS dock to phospo-tyrosines and induces the phosphorylation cascade of 
the Ras/Raf/MAPK/ERK pathway, culminating in activation of p90 ribosomal S6K1 (p90 
RSK), which phosphorylates and inhibits TSC. Insulin or IGF-1 binding to insulin/IGF-1 
receptor (IR/IGF-1R) recruits PI3K (either directly through p85 regulatory domain SH2 
domains or through insulin receptor substrate 1 (IRS-1). PI3K catalyzes the conversion 
of PIP2 to PIP3, which recruits PDK1 and Akt via their pleckstrin homology (PH) 
domains. PDK1 phosphorylates Akt on T308, and Akt phosphorylates TSC on inhibitory 
sites. Phosphorylation of TSC disrupts TSC complex integrity and association with the 
lysosomal membrane, allowing Rheb to activate mTORC1 on the lysosomal surface. 
Activation of EGFR and IR/IGF-1R leads to recruitment of mTORC2 to the plasma 
membrane via the PH domain of the mTORC2 partner protein mSin1. mTORC2 
phosphorylates Akt on S473 at the plasma membrane to boost Akt activity to a 
maximum level.  The cytosolic leucine sensor, Sestrin1, activates mTORC1 through the 










Figure 1.3: Raptor domain structure. Raptor contains a N-terminal raptor N-terminus 
conserved (RNC) domain, short tandem HEAT repeats, and C-terminal tandem WD40 
repeats. ERK1/2 phosphorylates Raptor on S8, S696, and S863 (46), and p90 RSK1/2 
phosphorylates S719, S721, and S722 (45) to activate mTORC1, both in response to 
MAPK pathway activation. mTOR phosphorylates Raptor S863, priming Raptor for 
subsequent phosphorylation on S855 and S859 by unknown kinases to activate 
mTORC1 (48). mTOR also phosphorylates Raptor S859 with no defined function (47). 
AMPK phosphorylates Raptor S722 and S792 to suppress mTORC1 during energetic 
stress (51). TBK1 phosphorylates Raptor S877 to inhibit mTORC1 following cellular 
stimulation with TBK1-activating innate immune agonists (50). NLK phosphorylates 






Figure 1.4: Rictor domain structure. Rictor is comprised of a N-terminal armadillo 
(ARM) repeats domain, HEAT repeats-like domain, and a C-terminal domain. S6K1 





Figure 1.5: mSin1 domain structure. The mSin1.1 isoform harbors a N-terminal 
domain (NTD), a conserved region in the middle (CRIM) domain, which mediates 
protein-protein interactions, a Ras-binding domain (RBD), and a pleckstrin homology 
(PH) domain. S6K1 phosphorylates mSin1 on T86 and T398 to induce mSin1 












Figure 1.6: Structural domain elements of TBK1 and IKKe. TBK1 (729 amino acids) 
and its homolog, IKKe (716 amino acids), are comprised of an N-terminal kinase 
domain, a ubiquitin-like domain (ULD), and a C-terminal scaffold/dimerization domain 
(SDD). TBK1 and IKKe require K63-linked polyubiquitination at lysine 30 and 401 to 
















Figure 1.7: TLR-mediated activation of TBK1. Engagement of TLR-4 by bacterial 
lipopolysaccharide (LPS) induces receptor dimerization and recruitment of the adaptors 
TRIF and TRAM. Double-stranded RNA (dsRNA) viruses are endocytosed and detected 
by TLR-3 located on endolysosomal membranes, leading to the recruitment of TRIF. 
Adaptor recruitment to TLR-4 and TLR-3 leads to the recruitment and activation of 
TBK1 (via phosphorylation on S172). TBK1 phosphorylates IRF-3/7 on multiple 
regulatory sites to induce their homodimerization and nuclear translation, where they 
upregulate the transcription of INF-a/b and interferon stimulated genes, culminating in 










Chapter 2  
 
 
The Innate Immune Kinase TBK1 Directly Increases mTORC2 Activity and 
Downstream Signaling to Akt 
 
2.1 Abstract 
 TBK1 (TANK-binding kinase 1) responds to microbial pathogens to initiate 
cellular responses critical for host innate immune defense. We found previously that 
TBK1 phosphorylates mTOR (mechanistic target of rapamycin) (on S2159) to increase 
mTOR complex 1 (mTORC1) activity and signaling in response to the growth factor 
EGF and the viral dsRNA mimetic poly (I:C). mTORC1 and the less well studied 
mTORC2 respond to diverse cues to control cellular metabolism, proliferation, and 
survival. Here we demonstrate that TBK1 activates mTOR complex 2 (mTORC2) 
directly to increase Akt phosphorylation at physiological levels of protein expression. We 
find that TBK1 phosphorylates mTOR S2159 within mTORC2 in vitro, phosphorylates 
mTOR S2159 in cells, and interacts with mTORC2 in cells. By studying MEFs lacking 
TBK1, as well as MEFs, macrophages, and mice bearing an Mtor S2159A knock-in 
allele (MtorA/A), we show that TBK1 and mTOR S2159 phosphorylation increase 
mTORC2 catalytic activity and promote mTOR-dependent downstream signaling to Akt 
in response to several growth factors and poly (I:C). While microbial-derived stimuli 
activate TBK1, we find that growth factors fail to activate TBK1 or increase mTOR 




with growth factors in parallel to increase mTORC2 (and mTORC1) signaling. 
Collectively, these results reveal crosstalk between TBK1 and mTOR complexes 
(mTORCs), key nodes within two major signaling systems. As TBK1 and mTORCs have 
each been linked to tumorigenesis and metabolic disorders, these kinases may work 
together in a direct manner in a variety of physiological and pathological settings. 
 
2.2 Introduction 
 TBK1 and its tissue-restricted orthologue IKKe mediate innate immunity against 
pathogenic viruses and bacteria in response to microbial-derived stimuli (202,288-291). 
Viral dsRNA and bacterial LPS bind to and activate the pathogen recognition receptors 
(PRRs) toll-like receptor 3 (TLR3) and TLR4, respectively (202,288-291). TLR3 and 4 
activate the kinases TBK1 and IKKe through phosphorylation of their activation loop 
sites on S172 by an unknown upstream kinase or through oligomerization and activation 
loop site auto-phosphorylation on S172 (206,207,292,293). TBK1/IKKe in turn 
phosphorylate the transcription factors IRF3 and 7, resulting in their translocation into 
the nucleus where they induce expression of type I interferons (i.e. IFNa/b), multi-
functional cytokines that initiate host defense responses while limiting tissue damage 
(215,294). 
 In prior work, we found that TBK1 phosphorylates mTOR on S2159, which 
increases mTOR complex 1 (mTORC1) signaling, mTORC1-mediated cell growth (i.e. 
cell size/mass) and cell cycle progression, and the production of IFNb (44,104). This 
positive role for TBK1 in mTORC1 signaling has been confirmed in other studies 




treatment with the TBK1/IKKe inhibitor amlexanox or TBK1 knockout in MEFs reduced 
phosphorylation of Akt on S473, an important metabolic kinase and target of PI3K (44). 
This observation agrees with other studies (177,199,295-297), several of which 
reported that TBK1 phosphorylates Akt S473 directly (177,199,297). As Akt S473 
represents an established target of mTOR complex 2 (mTORC2) (30,57,149,298), we 
investigated more fully, the mechanism by which TBK1 promotes Akt phosphorylation, 
testing the hypothesis that TBK1 directly activates mTORC2 and its downstream 
signaling to Akt. 
 The mechanistic target of rapamycin (mTOR) comprises the catalytic kinase core 
of two known multi-subunit mTOR complexes (mTORCs) (12,57,149). The scaffolding 
protein Raptor defines mTORC1 (14,15), while the scaffolding protein Rictor defines 
mTORC2 (26,299). These mTORCs integrate a diverse array of environmental cues to 
control cell physiology appropriate for cell type and context. Indeed, aberrant mTORC 
function contributes to pathologic states including oncogenesis and obesity-linked 
metabolic disorders (12,57,140,149). Despite the physiological importance of mTOR, 
our knowledge of the upstream regulation of mTORCs remain incompletely defined, in 
particular mTORC2. mTORC1 drives anabolic cellular processes (i.e. protein, lipid, and 
nucleotide synthesis) in response to the coordinated action of nutrients (i.e. amino acids 
and glucose), growth factors (i.e. EGF and IGF-1), and hormones (i.e insulin) to control 
cell metabolism and promote cell growth (i.e. mass/size) and proliferation 
(12,57,60,149). The insulin/IGF-1 pathway represents the best-characterized activator 
of mTORC1, which utilizes PI3K signaling to Akt, TSC, and Rheb to activate mTORC1 




phosphorylates a diverse set of targets (134,135), with S6K1 T389 phosphorylation 
serving as a widely employed readout of mTORC1 activity in intact cells. 
 Growth factors and hormones also activate mTORC2 in a manner that requires 
PI3K. It is important to note that the upstream regulation of mTORC2 remains 
significantly less well defined than mTORC1 (12,35,57,149,301). Recently, the energy 
sensing kinase AMPK was shown to activate mTORC2 directly to promote cell survival 
during energetic stress (43). In addition, the stress inducible protein Sestrin2 was shown 
to activate mTORC2 (302). mTORC2 phosphorylates Akt on S473, a widely employed 
readout of mTORC2 activity in intact cells (30,149,298). Akt functions as a key mediator 
of PI3K signaling that controls diverse aspects of cell physiology (301,303). Akt 
activation absolutely requires phosphorylation of its activation loop site on T308 by 
PDK1. Phosphorylation of its hydrophobic motif site on S473 by mTORC2 activates Akt 
further to a maximal level and controls substrate preference (28). While not well 
understood, Akt S473 phosphorylation promotes and/or stabilizes Akt T308 
phosphorylation, as increases or decreases in Akt P-S473 often result in 
correspondingly similar changes in Akt P-T308 (30,43,304). It is important to note that in 
addition to mTORC2, several other kinases have been identified as Akt S473 kinases, 
including DNA-PK, ATM, and ILK, and more recently TBK1 and IKKe (177,199,297,304). 
Functionally, mTORC2 controls cell metabolism, modulates the actin cytoskeleton, and 
promotes cell survival (12,26,57,149,299,305). 
 Beyond its well-known role in innate immunity, TBK1 has been implicated in 
oncogenesis and metabolic disorders linked to obesity such as type 2 diabetes, similar 




KRas transformed cells, TBK1 promotes cell proliferation and survival and the growth of 
tumor explants in vivo, with either mTORC1 or Akt suggested as downstream mediators 
of TBK1 action (177,199,267,278,279,295,296,306,307). In addition, elevated 
expression of the TBK1 orthologue IKKe contributes to breast cancer oncogenesis 
(269,306). In diet-induced obese mice, adipocyte specific knockout of TBK1 decreases 
Akt S473 phosphorylation in white adipose tissue, increases insulin resistance and pro-
inflammation, and impairs glucose homeostasis (285,310), a phenotype that overlaps 
with those resulting from adipocyte-specific knockout of Raptor (mTORC1) or Rictor 
(mTORC2) (138,140,141). Moreover, treatment of obese mice or human patients with 
amlexanox, or knockout of TBK1, Raptor (mTORC1 partner protein), or S6K1 (mTORC1 
substrate) in mouse adipocytes, reduces adiposity and body mass, in part due to 
increased energy expenditure (285,309-311). 
 To better understand how TBK1 contributes to health and disease, we 
investigated the molecular mechanism by which TBK1 controls the phosphorylation of 
Akt. We find that TBK1 phosphorylates mTOR to activate mTORC2 directly, resulting in 
increased Akt phosphorylation during cellular treatment with growth factors and the 
innate immune agonist poly(I:C). This work not only elucidates the poorly defined 
upstream activation of mTORC2, but it improves our understanding of the contribution of 
TBK1 and mTORCs to physiology and pathologic conditions such as tumorigenesis and 
obesity-linked metabolic disorders. 
 
2.3 Results 




 To elucidate the mechanism by which TBK1 positively controls Akt 
phosphorylation, we first analyzed TBK1 wild type (TBK1+/+) and knockout (TBK1-/-) 
MEFs. TBK1-/- MEFs displayed significantly reduced phosphorylation of Akt S473 (Fig 
2.1) across an EGF time course, consistent with prior work (44,177,199). TBK1-/- MEFs 
also displayed reduced Akt T308 phosphorylation in response to EGF (Fig 2.2), and the 
active-site mTOR inhibitor Torin1 ablated both Akt P- S473 and P-T308 (Fig 2.1, 2.2). 
These data are consistent with mTORC2 functioning as a major Akt S473 kinase 
(30,298) and with many reports that Akt S473 phosphorylation promotes Akt T308 
phosphorylation (30,43,304). Consistent with our prior work (44), TBK-/- MEFs displayed 
reduced S6K1 T389 phosphorylation, confirming that TBK1 promotes mTORC1 
signaling (Fig 2.1). To confirm that reduced EGF-stimulated Akt phosphorylation in 
TBK1-/- MEFs results from loss of TBK1, we stably expressed vector control or Flag-
tagged TBK1 in TBK1-/- MEFs by lentiviral transduction followed by puromycin selection. 
We selected several independent clones in which expression of exogenous Flag- TBK1 
matched endogenous TBK1, as our prior work found that overexpression of TBK1 
functions in a dominant negative manner to inhibit mTORC1 signaling (44), similar to 
overexpression of the mTORC1 subunit Raptor, an artifact common for proteins with 
scaffolding function. Expression of Flag-TBK1 rescued the reduced Akt S473 
phosphorylation displayed in TBK1 -/- MEFs stimulated with EGF (Fig 2.3). Moreover, 
stable expression of kinase-dead Flag-TBK1 failed to rescue P-Akt S473 (Fig 2.4). 
These results indicate that the kinase activity of TBK1 rather than its scaffolding function 
promotes Akt phosphorylation. Consistent with this conclusion, the TBK1/IKKe inhibitor 




HEK293 cells (Fig 2.6). Taken together, these results indicate that TBK1 kinase activity 
promotes mTOR dependent phosphorylation of Akt S473 and T308 during EGF 
stimulation. 
 
mTORC2 serves as a major link between TBK1 and Akt S473 phosphorylation at 
endogenous protein levels 
 Subsequent to the identification of mTORC2 as the major Akt S473 kinase 
(30,149,298), several groups demonstrated that TBK1 and IKKe phosphorylate Akt 
S473 and T308 directly (177,199,297). As we found that TBK1 phosphorylates mTOR to 
increase mTORC1 activity and signaling (44), we sought to clarify roles for TBK1 vs. 
mTOR in phosphorylation of Akt. We therefore assessed effects of mTOR inhibition 
across an EGF time course. We found that Torin1 ablated Akt S473 phosphorylation 
and reduced Akt T308 phosphorylation at each time point (1-30 minutes) following EGF 
stimulation of TBK1+/+ and TBK1-/- MEFs (Fig 2.7). Consistent with our prior work, TBK1 
knockout reduced S6K1 P-T389 (i.e. mTORC1 signaling) and mTOR auto-
phosphorylation on S2481 (44). It is important to note that mTOR S2481 auto-
phosphorylation represents a simple method to monitor total mTOR or mTORC specific 
catalytic activity in intact cells (42). These results indicate that in this setting, TBK1 
plays a negligible role in Akt S473 phosphorylation, and thus mTOR represents the 
major Akt S473 kinase in MEFs. 
 We next investigated whether elevated levels of TBK1 and/or Akt enables TBK1 
to directly engage and phosphorylate Akt. We therefore overexpressed increasing 




exogenous Flag-TBK1 WT increased Akt P-S473 (Fig 2.8). Torin1 reduced Akt P-S473 
at low to mid doses of Flag-TBK1, indicating mTOR dependency, while higher doses 
displayed less Torin1 sensitivity. We next co-transfected Flag-TBK1 together with Flag-
HA-Akt. The double Flag-HA tag allowed resolution of exogenous Akt (Flag-HA tagged) 
from endogenous Akt, enabling distinct assessment of phosphorylation on each of these 
two Akt populations. As before, TBK1 overexpression increased phosphorylation of 
endogenous Akt in a Torin1 sensitive manner at low doses. Upon co-expression of 
Flag-TBK1 with Flag-HA-Akt, however, Akt P-S473 became Torin1 resistant at even the 
lowest dose of Flag-TBK1 (Fig 2.9). These data indicate that, in the context of TBK1 
and Akt over-expression, TBK1 phosphorylates Akt S473 independently of mTOR 
activity, as reported in prior work (177,199). At physiological levels of protein, however, 
TBK1 requires mTOR activity to mediate Akt S473 phosphorylation. By in vitro kinase 
assay, we confirmed that TBK1 phosphorylates recombinant Akt1 on S473 (Fig 2.10), 
consistent with other groups (177,199,297), and TBK1 phosphorylates a recombinant 
GST-mTOR fragment on S2159 (Fig 2.11), consistent with our prior work (44). 
Importantly, we confirmed that TBK1 phosphorylates wild type but not S2159A Myc-
mTOR immunoprecipitated from transfected cells (Fig 2.12). Thus, TBK1 
phosphorylates diverse substrates with dissimilar consensus phosphorylation motifs, 
particularly at elevated levels of expression of kinase and/or substrate. 
 To examine a potential role for TBK1 in the phosphorylation of Akt S473 in the 
absence of confounding mTORC2 activity, we analyzed MEFs lacking the critical 
mTORC2 partner protein Rictor.  As expected, Rictor-/- MEFs expressing vector control 




exogenous re-expression of HA-Rictor rescued this phenotype in a manner sensitive to 
the mTOR inhibitor Ku-0063794 (Fig 2.13). Consistent with Fig 2.5 and 2.6, amlexanox 
inhibited Akt P-S473 in the rescued Rictor-/- MEFs, indicating dependence on TBK1 
activity (Fig 2.13). With long blot exposure time, however, EGF increased Akt P-S473 in 
the Rictor-/- MEFs in a Ku-0063794 sensitive, but amlexanox resistant, manner (Fig 
2.13, 2.14). While somewhat unexpected, the Ku-0063794 sensitivity reveals that 
MEFs lacking Rictor express crippled mTORC2 that still retains a low level of activity 
toward Akt. In agreement, Xie et al. found that mTOR inhibition with Torin1 reduced Akt 
P-S473 in response to PDGF in Rictor-/- MEFs (177). Therefore, these data indicate that 
mTOR rather than another kinase (i.e. TBK1) mediates Akt S473 phosphorylation in 
Rictor-/- MEFs. The amlexanox resistance of Rictor-/- MEFs suggests that TBK1 activity 
contributes negligibly to Akt phosphorylation in the context of crippled mTORC2. 
Curiously, shRNA-mediated knockdown of TBK1 in Rictor-/- MEFs reduced Akt P-S473 
(Fig 2.14), consistent with Xie et al. (177). This finding suggests that the scaffolding 
function of TBK1 may contribute to mTORC2-mediated phosphorylation of Akt S473, at 
least in cells lacking physiologically intact mTORC2. Taken together, these data indicate 
that mTORC2 represents a critical link between TBK1 and Akt S473 phosphorylation at 
physiological levels of protein expression. 
 
mTOR S2159 phosphorylation promotes mTORC2 signaling in response to EGF 
 In prior work we generated genome edited mice bearing an alanine knock-in 
substitution at Mtor S2159 using CRISPR/Cas9 technology (44). By studying bone 




S2159A knock-in mice (MtorA/A), we demonstrated that mTOR S2159 phosphorylation is 
required for mTORC1 signaling and IFNb production in macrophages stimulated with 
innate immune agonists (i.e. poly(I:C) and LPS) (44). Thus, we next investigated a 
potential direct link between TBK1 and mTORC2 by studying the role of mTOR S2159 
phosphorylation in control of mTORC2 signaling. To do so, we isolated littermate 
matched MEFs from Mtor+/+ and MtorA/A mice (pair #1 MEFs), subjected them to 
spontaneous immortalization, and analyzed their response to EGF following serum 
deprivation. Relative to MEFs from Mtor+/+ mice (i.e. mTOR+/+ MEFs), MEFs from 
MtorA/A mice (i.e. mTORA/A MEFs) displayed significantly reduced Akt P-S473 (Fig 2.15) 
and Akt P-T308 (Fig 2.16) across an EGF time course. mTORA/A MEFs also displayed 
reduced S6K1 P-T389 and mTOR S2481 auto- phosphorylation (Fig 2.15). Activation of 
the MAPK/ERK pathway in response to EGF remained unperturbed in the mTORA/A 
MEFs (as monitored by the phosphorylation of ERK1 and 2 on T202/Y204), indicating 
intact activation of EGF-receptor signaling to MAPK/ERK in mTORA/A MEFs (Fig 2.15). 
Importantly, we observed reduced Akt P-S473 and S6K1 P-T389 in response to EGF in 
a second, independently derived pair of mTOR+/+ and mTORA/A MEFs (pair #2 MEFs) 
(Fig 2.17). These data demonstrate that mTOR S2159 phosphorylation increases 
mTOR catalytic activity and promotes mTORC2 and 1 signaling upon cellular 
stimulation with EGF. 
 We next asked whether EGF activates TBK1 by monitoring TBK1 
phosphorylation on its activation loop site (S172). We found that EGF failed to increase 
TBK1 P-S172 in either mTOR MEFs (Fig 2.18) or TBK1 MEFs (Fig 2.19); as expected, 




2.19). Note that EGF also failed to increase TBK1 P-S172 in HEK293 cells (see (44)). 
These results demonstrate that EGF does not activate TBK1, at least in MEFs and 
HEK293 cells, and thus basal rather than EGF stimulated TBK1 activity supports 
mTORC1/2 signaling. 
 
TBK1 phosphorylates mTOR within mTORC2, interacts with mTORC2, and 
increases mTORC2 intrinsic catalytic activity 
 To further define the mechanism by which TBK1 promotes mTORC2 signaling, 
we asked whether recombinant TBK1 (re-TBK1) phosphorylates mTOR S2159 within 
mTORC2 directly. It is important to note that our prior work demonstrated that TBK1 
phosphorylates mTOR S2159 within mTORC1 (44). By in vitro kinase assay, we found 
that re-TBK1 increased mTOR P-S2159 on Rictor- associated mTOR 
immunoprecipitated from cells, and inclusion of the TBK1/IKKe inhibitor BX-795 in vitro 
blocked this increase (Fig 2.20). We next asked whether TBK1 and mTORC2 interact in 
cells. By co-immunoprecipitating endogenous proteins, we found that Rictor 
immunoprecipitates pulled down TBK1 in TBK1+/+,  but not TBK1-/- MEFs (Fig 2.21). 
 Together, these data support a mechanism whereby TBK1 interacts with 
mTORC2 and subsequently mediates the direct phosphorylation of mTOR S2159 within 
mTORC2. We next asked whether EGF increases mTOR S2159 phosphorylation and 
whether TBK1 promotes mTOR S2159 phosphorylation in intact cells. EGF failed to 
increase P-S2159 on mTOR immunoprecipitated from TBK1+/+ or mTOR+/+ MEFs (Fig 
2.22, 2.23). Importantly, TBK1 knockout from MEFs reduced mTOR P-S2159 (Fig 2.22), 




S2159A knock-in. We speculate that the remaining mTOR P-S2159 found in TBK1-/- 
MEFs results from IKKe-mediated phosphorylation of mTOR. Indeed, while 
IKKe expression is generally tissue-restricted and extremely low in non-immune cells, 
MEFs indeed express detectable levels of IKKe (Fig 2.22, 2.23). These data 
demonstrate that TBK1 mediates mTOR S2159 phosphorylation in vitro and in intact 
cells and support the conclusion that basal rather than EGF stimulated TBK1 kinase 
activity mediates mTOR P-S2159 to promote mTORC2 signaling. 
 We next asked whether TBK1 and mTOR S2159 phosphorylation increase the 
intrinsic catalytic activity of mTORC2 by in vitro kinase assay. To do so, we 
immunoprecipitated Rictor from TBK1+/+ vs. TBK1-/- MEFs and from mTOR+/+ vs. 
mTORA/A MEFs after EGF stimulation of serum deprived cells. The Rictor 
immunoprecipitates were washed, incubated in kinase buffer with ATP and recombinant 
His-Akt1 as substrate, and the ability of Rictor-associated mTOR to phosphorylate Akt 
S473 in vitro was monitored by western blot. In both TBK1+/+ MEFs (Fig 2.24) and 
mTOR+/+ MEFs (Fig 2.25), EGF increased mTORC2 catalytic activity in a Torin1-
sensitive manner, as expected. The fold increase in mTORC2 catalytic activity mediated 
by EGF, however, was reduced in TBK1-/- MEFs (Fig 2.24) and mTORA/A MEFs (Fig 
2.25). To assess the role of TBK1 and mTOR S2159 phosphorylation in control of 
mTORC2 catalytic activity by an independent approach, we monitored S2481 auto-
phosphorylation on Rictor associated mTOR (i.e. mTORC2). Similar to results obtained 
with mTORC2 in vitro kinase assays, the fold increase in mTOR S2481 auto-
phosphorylation mediated by EGF was reduced in TBK1-/- (Fig 2.26) and mTORA/A 




phosphorylation increase mTORC2 catalytic activity. 
 
TBK1 and mTOR S2159 phosphorylation increase mTORC2 (and mTORC1) 
signaling in response to diverse growth factors 
 We next investigated whether the positive role of mTOR S2159 phosphorylation 
in mTORC2 signaling extends to a broader set of growth factors. We thus interrogated 
mTORC2 signaling to Akt, as well as mTORC1 signaling to S6K1, in mTOR+/+ vs. 
mTORA/A MEFs in response to several growth factors known to activate mTORC2 and 1 
signaling. We first assessed the role of mTOR P-S2159 in control of mTORC2 and 1 
signaling in MEFs cultured in complete media (i.e. DMEM/FBS [10%]) containing serum 
growth factors. mTORA/A MEFs as well as TBK1-/- MEFs displayed reduced Akt S473 
and S6K1 T389 phosphorylation (Fig 2.28). Treatment of cells with Torin1 ablated these 
phosphorylation events, indicating that mTOR activity is required for mTORC2 and 1 
signaling in complete media (Fig 2.28). We next assessed the role of mTOR P-S2159 in 
control of mTORC2 and 1 signaling in response to stimulation of MEFs with fetal bovine 
serum (FBS), platelet-derived growth factor (PDGF) (a major constituent of FBS), and 
insulin (which acts through IGF-1 receptors in MEFs) following serum deprivation. 
Similar to their response to EGF, mTORA/A MEFs displayed reduced Akt P-S473 and 
S6K1 P-T389 in response to all three growth factors with varying dynamics across a 
time course (Fig 2.29, 2.30, 2.31). In addition, all three growth factors failed to increase 
TBK1 P-S172 phosphorylation (Fig 2.32), suggesting that growth factor receptor 
signaling does not activate TBK1, at least in MEFs. These results indicate that mTOR 





 As TBK1 knockout MEFs displayed reduced Akt S473 and S6K1 T389 
phosphorylation upon amino acid stimulation following amino acid deprivation (295), we 
next examined a role for mTOR P-S2159 in control of these phosphorylation events in 
the absence or presence of amino acids. It is important to note that mTORC1 
localization and activity change dynamically in response to amino acids levels, with the 
majority of studies indicating that mTORC2 does not function in amino acid sensing 
(58,300,312-316). We cultured mTOR+/+ vs. mTORA/A MEFs, as well as TBK1+/+ vs. 
TBK1-/- MEFs, in DMEM lacking amino acids, but supplemented with dialyzed FBS for 
50 minutes; we then added back a 1x mixture of total amino acids (pH normalized to 
7.4) for 10 minutes. Amino acids increased S6K1 P-T389, but not Akt P-S473, in wild 
type MEFs, as expected (Fig 2.33). mTORA/A and TBK1-/- MEFs displayed reduced Akt 
P-S473 and S6K1 P-T389 in both the absence and presence of amino acids (Fig 2.33). 
Similar to wild type MEFs, amino acids increased S6K1 P-T389 but not Akt P-S473 in 
the mutant MEFs. Taken together, these results indicate that amino acids activate 
mTORC1, but not mTORC2 signaling, and TBK1 and mTOR P-S2159 support both 
mTORC1 and 2 signaling in parallel to growth factor and amino acid signaling pathways. 
 
TBK1 activity and mTOR S2159 phosphorylation increase TLR3-mediated 
mTORC2 signaling in macrophages 
 Our prior work demonstrated that TBK1 and mTOR S2159 phosphorylation 
promote mTORC1 signaling in macrophages upon activation of TLR-3 and 4, pathogen 




and mTOR P-S2159 in positive control of mTORC2 signaling in macrophages, we 
assayed how TBK1/IKKe inhibitors or Mtor S2159A knock-in modulated mTORC2 
signaling to Akt in response to TLR-3 activation with poly (I:C) (a viral dsRNA mimetic). 
In cultured RAW264.7 macrophages, poly(I:C) activated TBK1 (as monitored by 
increased TBK1 P-S172) and PI3K-dependent mTORC2 signaling (as monitored by the 
sensitivity of Akt P-S473 to the class I PI3K inhibitor BYL-719 and the mTOR inhibitor 
Ku-0063794 (Fig 2.34, 2.35). Inhibition of TBK1/IKKe with two different small molecules, 
amlexanox (Fig 2.34, 2.35) or BX-795, (Fig 2.35) (207) also reduced poly (I:C) induced 
Akt P-S473, demonstrating that TBK1/IKKe activity positively controls mTORC2 
signaling to Akt in RAW24.7 macrophages. 
 We next isolated primary bone marrow-derived macrophages (BMDMs) from 
Mtor+/+ and MtorA/A mice. As expected, poly (I:C) increased TBK1 P-S172 and mTOR-
dependent Akt P-S473 in wild type BMDMs (Fig 2.36). As in RAW264.7 macrophages, 
amlexanox suppressed Akt P-S473 to a basal level (Fig 2.36). Importantly, BMDMs 
from MtorA/A mice displayed reduced poly (I:C) induced Akt P-S473 (Fig 2.36), thus 
demonstrating a required role for mTOR S2159 phosphorylation in TLR-3-mediated 
activation of mTORC2 signaling. Consistent with our prior work (44), amlexanox or Mtor 
S2159A knock-in reduced mTORC1 signaling in RAW264.7 macrophages and BMDMs 
(Fig 2.34, 2.36). These results demonstrate that TBK1 activity, mTOR activity, and 
mTOR S2159 phosphorylation are required for mTORC2 signaling to Akt upon 
activation of TLR-3 in macrophages. Finally, to demonstrate a role for mTOR S2159 
phosphorylation in activation of mTORC2 signaling by TLR-3 in vivo, we injected Mtor+/+ 




found that spleen tissue from MtorA/A mice displayed reduced Akt S473 phosphorylation 
in response to poly (I:C) (Fig 2.37). Taken together, these results demonstrate that 
TBK1 phosphorylates mTOR S2159 to activate mTORC2 directly and increase 
downstream signaling to Akt in cultured cells and in vivo (Fig 2.38) (model cartoon). 
Moreover, they reveal that mTORC2 represents an essential link between TBK1 and 
Akt phosphorylation at physiological levels of protein expression. We find that in MEFs, 
basal TBK1 kinase activity signals in parallel to growth factors to augment mTORC2 
(and mTORC1) activity, as EGF and other growth factors increased mTORC1/2 
signaling in a TBK1 and mTOR P-S2159 dependent manner without increasing TBK1 
S172 or mTOR S2159 phosphorylation. The relationship between growth factor 
signaling and TBK1 activity appears to be context dependent, however, as growth 
factors were shown recently to activate TBK1 (i.e. increase TBK1 P-S172) in lung 
cancer cells  (296) (see Discussion). In macrophages, TLR-3 signaling increases TBK1 
and mTORC1/2 activity in a linear pathway (Fig 2.38). It is important to note that other 
groups have reported that the PI3K/Akt pathway signals in parallel to, but independently 
of, TBK1/IKKe to promote full activation of IRF-3 and the innate immune response. 
Specifically, dsRNA-induced phosphorylation of TLR-3 on tyrosine 759 resulted in the 
recruitment of PI3K to the cytoplasmic domain of the receptor, and this mechanism 
further increased phosphorylation of IRF-3, effectively rendering it transcriptionally 
competent to drive innate immune target gene expression (317). This group proposed a 
two-step model in which initial phosphorylation of IRF-3 by TBK1, together with 
subsequent phosphorylation on additional serine/threonine residues (presumably by 




demonstrated that influenza A virus induced IRF-3 binding to interferon-sensitive 
response elements (ISREs) within the promoter of C-X-C motif chemokine ligand 10 
(CXCL-10) to induce its expression, and several other groups have demonstrated that 
the influenza A viral protein NS1 activates the PI3K/Akt pathway (318-320). 
 
2.4 Discussion 
 Several studies have demonstrated a positive role for TBK1 in Akt 
phosphorylation in various contexts. Increasing or decreasing TBK1 activity by various 
approaches in many cell types (i.e. MEFs, HEK293 cells, U2OS cells, HeLa cells, MNT1 
melanoma cells, or HCT116 colorectal cancer cells) led to correspondingly similar 
changes in Akt S473 phosphorylation (177,199,295,296). These observations, together 
with evidence that mTORC2 serves as a major Akt S473 kinase (30,57,149,298), and 
our prior work that TBK1 directly activates mTORC1 (44), prompted us to investigate 
whether mTORC2 represents a missing link between TBK1 and Akt phosphorylation. 
 While it is challenging to demonstrate definitely that a kinase (i.e. TBK1) 
phosphorylates a substrate (i.e. mTOR) directly in intact cells rather than indirectly in a 
complex, several lines of evidence considered together support our model that TBK1 
phosphorylates mTOR S2159 directly to increase mTORC2 activity and signaling to Akt 
(Fig 2.38): TBK1 phosphorylates mTOR S2159 within mTORC2 in vitro; TBK1 and 
mTORC2 co-immunoprecipitate and TBK1-/- MEFs display reduced mTOR P-S2159 in 
intact cells; TBK1-/- MEFs and mTORA/A MEFs (lacking mTOR P-S2159) display 
reduced mTOR dependent Akt P-S473 and Akt P-T308 in response to EGF; Rictor-/- 




sensitive; TBK1 overexpression at low levels increases Akt P-S473 in a largely Torin1 
sensitive manner; and finally, both TBK1-/- MEFs and mTORA/A MEFs display reduced 
mTORC2 intrinsic catalytic activity in response to EGF, as measured by mTORC2 IVK 
assay and by Rictor-associated mTOR S2481 autophosphorylation. To support these 
results in immortalized cells, we also provide evidence that in primary macrophages in 
culture (i.e. BMDMs) and spleen tissue in vivo, mTOR S2159 phosphorylation is 
required for Akt S473 phosphorylation in response to TBK1 activation with poly (I:C). In 
addition, Zhao et al found that adipocyte-specific knockout of TBK1 in diet-induced 
obese mice reduced Akt P-S473 in response to insulin in white adipose tissue (285). 
Taken together, these results argue that TBK1-mediated mTOR S2159 phosphorylation 
promotes mTORC2 signaling to Akt. 
 Several groups identified TBK1 as a direct Akt S473 and T308 kinase 
(177,199,297). We found that at physiological levels of TBK1 and Akt expression, the 
ability of growth factors or poly (I:C) to increase Akt S473 phosphorylation in a 
detectable manner required mTOR activity. mTOR inhibition also reduced Akt P-T308, a 
finding consistent with the observation that Akt S473 phosphorylation promotes and/or 
stabilizes Akt T308 phosphorylation (30,43,304). We found that overexpression of TBK1 
increased Akt P-S473, similar to earlier work (177,199,297). This effect was largely 
dependent on mTOR activity at low to mid doses of TBK1 but displayed modest mTOR 
independence at higher doses. When both TBK1 and Akt were overexpressed, 
however, TBK1 increased Akt P-S473 in an mTOR-independent manner. Taken 
together, these data indicate that at physiological levels of TBK1 and Akt expression, 




 Pathological or unique physiological contexts may modify mechanisms governing 
Akt S473 and T308 phosphorylation. For example, tissue-specific knockout of Rictor or 
mTOR from cardiac or skeletal muscle failed to ablate Akt S473 phosphorylation (an 
unexpected finding) (177,321-323). Even more surprising, mTOR knockout cardiac 
muscle displayed elevated Akt P-S473 (177,323). This finding prompted Xie et al to 
search for alternate Akt S473 kinases. Upon discovering TBK1 as an Akt S473 and 
T308 kinase, they noted that mTOR knockout cardiac muscle displayed elevated TBK1 
expression (177). Thus, in this context of elevated TBK1 expression, TBK1 may 
phosphorylate Akt directly. Pathological contexts may also render Akt S473 
phosphorylation TBK1 independent. For example, TBK1 inactivation reduced S6K1 
T389 but not Akt S473 phosphorylation in response to growth factors in A549 human 
lung adenocarcinoma cells or primary mouse lung cancer epithelial cells (296). 
Therefore, we propose that in stress-related contexts (i.e. knockout of the essential 
kinase, mTOR), oncogenic contexts, or other pathological contexts, cells and tissues 
may re-wire signaling and metabolism by upregulating expression of TBK1/IKKe (or 
other Akt S473 kinases). Such an adaptive response may in turn enable TBK1/KKe (or 
other kinases) to directly phosphorylate Akt S473 and/or T308, thus increasing Akt 
activity in order to mitigate the pathologic insult and improve metabolic homeostasis 
and/or provide a proliferative or survival advantage. 
 Mechanisms governing regulation of TBK1 kinase activity in non-immune cells 
remain poorly defined. Our results indicate that in MEFs, growth factors increase 
mTORC2 signaling in a TBK1 and mTOR P-S2159 dependent manner without 




phosphorylation. We therefore conclude that in this context, the basal kinase activity of 
TBK1 promotes mTORC2 signaling in parallel to growth factors. It is important to note, 
however, that stimulation of human A549 lung cancer cells and primary mouse lung 
cancer cells with several different growth factors (i.e. EGF, FBS, and insulin) increased 
TBK1 S172 phosphorylation, which required TBKBP1 (TBK binding protein 1), a TBK1 
adaptor protein (296). We speculate that differential expression of numerous TBK1 
adaptors explains differences in cellular context that underlies regulation of TBK1 
activity by growth factors. These adaptors may also differentially control TBK1 
subcellular localization and/or TBK1 substrate preference (200,292,307,324). 
 Taken together, our results identify TBK1 as a direct activator of mTORC2 in 
physiological contexts, which expands our limited understanding of mTORC2 regulation. 
In addition, they establish the TBK1-mTORC2 pathway as a potential target for 
therapeutic intervention to treat cancer and obesity linked metabolic disorders. 
 
2.5 Experimental Procedures 
Materials 
General chemicals were from Thermo Fisher or Sigma. Protein A- and G-Sepharose 
Fast Flow were from GE Healthcare; NP40, Brij35, and CHAPS (3-[(3-cholamidopropyl)-
dimethylammonio]-1- propanesulfonate) detergents were from Pierce; cOmplete 
Protease Inhibitor Cocktail (EDTA-free) tablets were from Millipore Sigma 
(#11836170001); Immobilon-P polyvinylidene difluoride (PVDF) membrane (0.45 μM) 
was from Millipore; Bradford Reagent for protein assays was from Bio Rad (#5000001); 




(Bright Star) or Advansta (Western Bright Sirius HRP substrate). Recombinant active 
GST-TBK1 was from Thermo Fisher/ Life Technologies (#PV3504); recombinant His-
Akt1 was from EMD Millipore (#14-279); recombinant GST-mTORf (containing a 30 
fragment of mTOR encoding amino acids 2144- 2175) was generated as described (44). 
 
Antibodies 
The following antibodies from Cell Signaling Technology (CST) were used in this study 
(all rabbit polyclonal antibodies, unless otherwise noted): Akt (#9272); Akt P-S473 
(#4060; rabbit mAb D9E XP);  Akt P-T308 (#4056, rabbit mAb 244F9); TBK1 (#3013; or 
#3504, rabbit mAb D1B4); TBK1 P-S172 (#5483, rabbit mAb D52C2 XP); S6K1 
(#9202); S6K1 P-T389 (#9205; #9234, rabbit mAb 108D2; #9206, mouse mAb IA5); 
mTOR (#2972); MAPK (#9102); MAPK P-T202/Y204 (#4370, rabbit mAb D13.14.4E 
XP); GST (#2624; mouse mAb 26H1); IgG-conjugated Sepharose beads (#3423); 
Rictor- conjugated Sepharose beads (#5379). The following antibodies were from other 
commercial vendors: mTOR P-S2481 (MilliporeSigma #09-343); Myc (Millipore Sigma 
#05-419, mouse mAb 9E10); HA.11 (BioLegend # 901513, mouse mAb 1612B). The 
following custom, anti-peptide polyclonal antibodies were generated by us in-house with 
assistance from a commercial vendor: Rictor (amino acids 6-20; Covance; as described 
(48,325)); mTOR (amino acids 221-237, Covance; as described (48,325)); mTOR P-
S2159 (Millipore; as described (44)). 
 
Plasmids 




obtained from Dr. A. Saltiel (UCSD School of Medicine, Institute for Diabetes and 
Metabolic Health; San Diego, CA). pcDNA3/Flag-HA-Akt was obtained from Addgene 
(#9021). pRK5/Myc-mTOR WT was originally from Dr. D. Sabatini (MIT and the 
Whitehead Institute, Boston, MA) and obtained via Addgene (#1861). pRK5/Myc-mTOR 
S2159A was generated via site-directed mutagenesis as described (44))). pCI/HA- 
Rictor was from Dr. E. Jacinto (Rutgers University, New Brunswick, NJ). 
 
Cell culture, transfection, and drug treatments 
All cell lines used in this study (i.e. MEFs, HEK293, RAW264.7 murine macrophages, 
and primary mouse BMDMs) were cultured in DMEM that contained high glucose [4.5 
g/L], glutamine [584 mg/L], and sodium pyruvate [110 mg/L] (Thermo Fisher/ Life 
Technologies) supplemented with 10% fetal bovine serum (FBS) (Gibco/Invitrogen). 
Note that dialyzed FBS was used to culture the RAW264.7 macrophages and BMDMs. 
Cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. HEK293 
cells (from ATCC) were transfected using Mirus Trans-It LT1 in accordance with 
manufacturer’s instructions and lysed ~24 to 48 hr. post-transfection. To stimulate cells 
with growth factors, MEFs and HEK293 cells were first serum starved via incubation in 
DMEM containing 20 mM Hepes pH 7.2 overnight, ~20 hr. The cells were then 
stimulated with EGF [25 or 50 ng/mL] (Sigma Aldrich #E9644 and #E4127), FBS [10% 
final], PDGF [10 ng/mL] (EMD Millipore #GF149), or insulin [100 nM] (Thermo Fisher/ 
Life Technologies #12585) for various amounts of time (0-60 mins). To stimulate 
macrophages with innate immune agonists, RAW264.7 macrophages and BMDMs 




with poly(I:C) [30 ug/mL] (Sigma Aldrich #P1530) or ultrapure LPS [100 ng/ml] (InVivo 
Gen #tlrl-3pelps). Cells were treated with the following drugs: Torin1 [100 nM] (30 min) 
(shared by Dr. D. Sabatini), Ku-0063794 [100 nM] (30 min) (Tocris #3725); amlexanox 
[100 uM] (1-2 hr) (EMD Millipore #SML0517); BX-795 [10 uM] (30 min) (Millipore 
CalBiochem #204011) (30 min); BYL-719 [10 uM] (30 min) (Selleck; #1020). To amino 
acid deprive and stimulate cells, MEFs were first incubated for 50 min in RPMI media 
lacking all amino acids (Millipore Sigma; # R8758) but supplemented with dialyzed FBS 
[10%]. The cells were then acutely stimulated with amino acids for 10 min by adding a 
mixture of total amino acids (RPMI 1640 Amino Acid Solution) (Millipore Sigma; # 
R7131) to a final concentration of [1x] (the concentration of amino acids in RPMI 
medium). Note that the pH of this amino acid solution is quite basic, and thus the pH of 
this solution was first normalized to 7.4 prior to addition to cells in order to maintain 
physiological pH. As the RPMI 1640 Amino Acid Solution lacks glutamine, the amino 
acid mixture was supplemented with L-glutamine (Millipore Sigma; #59202C) prior to pH 
normalization and addition to cells. 
 
Cell lysis, immunoprecipitation, and immunoblotting 
Cells were washed twice with ice-cold PBS pH 7.4 and scraped into ice-cold lysis 
buffer A (10 mM KPO4 pH 7.2; 1 mM EDTA; 5 mM EGTA; 10 mM MgCl2; 50 mM b-
glycerophosphate; 1 mM sodium orthovanadate [Na3VO4]; a cocktail of protease 
inhibitors) containing NP-40 [0.5%] and Brij35 [0.1%], as described (325). 
To maintain detergent sensitive mTOR-partner protein interactions during Rictor or 




CHAPS [0.3%] detergent. Lysates were spun at 13,200 rpm for 5 min at 4°C, and the 
post-nuclear supernatants were collected and incubated on ice (15 min). Bradford assay 
was used to normalize protein levels for immunoblot or immunoprecipitation analysis. 
For immunoprecipitation, whole cell lysates were incubated with antibodies for 2 hr. at 
4°C, followed by incubation with Protein G- or A- Sepharose beads for 1 hr. Sepharose 
beads were washed three times in lysis buffer and resuspended in 1x sample buffer. 
Samples were resolved on SDS-PAGE and transferred to PVDF membranes in Towbin 
transfer buffer containing 0.02% SDS, as described (325). Immunoblotting was 
performed by blocking PVDF membranes in Tris-buffered saline (TBS) pH 7.5 with 0.1% 
Tween-20 (TBST) containing 3% non-fat dry milk, as described (325), and incubating 
the membranes in TBST with 2% bovine serum albumin (BSA) containing primary 
antibodies or secondary HRP-conjugated antibodies. Blots were developed by ECL and 
detected digitally with a Chemi-Doc-It System (UVP). 
 
Lentiviral transduction 
TBK1-/- MEFs stably expressing Flag-TBK1 (wild type or kinase dead K38M) were 
generated by lentiviral transduction. Flag-TBK1 was subcloned into a modified lentiviral 
vector, pHAGE-Puro-MCS (pPPM) (326) (modified by Amy Hudson (Medical College of 
Wisconsin) to include an expanded multiple cloning site, MCS). Lentivirus particles were 
packaged in HEK293T cells by co-transfection with empty pPPm vector or pPPM/Flag-
TBK1 together with pRC/Tat, pRC/Rev, pRC/gag-pol, and pMD/VSV-G using Mirus 
TransIT-LT1 transfection reagent. Supernatants containing viral particles were collected 




with fresh viral supernatants containing 8 µg/ml polybrene. 24 hr. post infection, cells 
were re-fed with DMEM/10% FBS supplemented with 10 µg/ml puromycin for 2-3 days 
to select for stably transduced cells, trypsinized, and plated at limiting dilution in order to 
isolate clones originating from single cells. TBK1-/- MEF clones transduced with wild type 
Flag-TBK1 lentivirus were analyzed for expression of exogenous Flag-TBK1 relative to 
expression of endogenous TBK1 found in wild type MEFs. TBK1-/- MEF clones 
expressing Flag-TBK1 at a level similar to endogenous TBK1 were chosen for analysis. 
Alternately, TBK1-/- MEFs transduced with wild type or kinase dead (K38M) Flag-TBK1 
were selected in puromycin and pooled for analysis. Rictor -/- MEFs (from Dr. E. Jacinto; 
Rutgers University, New Brunswick, NJ) stably expressing vector control or HA-Rictor 
were generated by lentiviral transduction and stable selection, as described (43). These 
rescued lines were maintained in DMEM/FBS [10%] containing puromycin [8 µg/mL]. To 
knockdown TBK1, Rictor-/- MEFs were infected with lentiviral particles encoding an 
shRNA targeting TBK1 (Sigma) (mouse TBK1 # TRCN0000323444; non-targeting # 
SHC016V) and then selected in puromycin [8 µg/mL] for 4 days. 
 
In vitro kinase assays 
Phosphorylation of recombinant His-Akt1 or GST-mTORf by recombinant active TBK1. 
In vitro kinase (IVK) assays were performed by incubating recombinant His-Akt1 [50 ng] 
or GST-mTORf [50 ng] substrates with recombinant active GST-TBK1 [50 ng] in kinase 
buffer containing 25 mM Tris-HCl pH 7.5,10 mM MgCl2, 1 mM DTT, and 200 µM ATP. 
Reactions were incubated at 30°C for 30 min and stopped by addition of sample buffer 




transferred to PVDF membrane, and immunoblotted. The phosphorylation of His-Akt1 
was measured using anti-Akt P-S473 antibodies, and the phosphorylation of GST-
mTORf was monitored using anti-mTOR P-S2159 antibodies. For certain IVK reactions, 
recombinant kinases were pre-incubated with BX-795 [10 µM] in kinase buffer on ice for 
30 min.   
 
Phosphorylation of Myc-mTOR or Rictor-associated mTOR isolated from cells by 
recombinant active TBK1. HEK293 cells were transfected with Myc-mTOR wild type or 
mutant S2159A, and lysates were immunoprecipitated with anti-Myc antibodies. Myc-
mTOR S2159A was generated by QuikChange mutagenesis, as described previously 
(104). Alternately, Rictor from non-transfected HEK293 cells was immunoprecipitated 
with anti-Rictor antibodies. After washing in lysis buffer and kinase buffer, the immune 
complexes (containing substrate) were incubated with recombinant active GST-TBK1 
[50 ng] in kinase buffer and ATP, as described above. The phosphorylation of Myc-
mTOR or Rictor-associated mTOR was monitored using anti-mTOR P-S2159 
antibodies. 
 
Phosphorylation of His-Akt1 by cellular mTORC2 (i.e., mTORC2 IVKs). mTORC2 in 
vitro kinase (IVK) assays was performed as described (43,70). Briefly, Rictor was 
immunoprecipitated from serum starved MEFs pre-treated without or with Torin1 [100 
nM] (30 min) and then stimulated without or with EGF [50 ng/mL] (10 min) (1-2 10 cm 
plates for each immunoprecipitate). After washing in lysis buffer and kinase buffer, the 




recombinant His-Akt1 [100 ng/reaction] in kinase buffer containing 25 mM HEPES, 100 
mM potassium acetate, and 1 mM Mgcl2 at 30°C for 30 mins. Certain reactions were 
also pre-treated with Torin1 [10 µM] in kinase buffer on ice for 30 min prior to initiating 
the IVK reaction. Immunoprecipitates were pre-incubated with Torin1 [10 µM] on ice (30 
min) and then were incubated with ATP [500 uM] and recombinant His-Akt1 [100 
ng/reaction] in kinase buffer containing 25 mM HEPES, 100 mM postassium acetate, 
and 1 mM Mgcl2, at 30°C for 30 min. 
 
Co-immunoprecipitation of TBK1 and mTORC2 
TBK1+/+ or TBK1-/- MEFs were lysed in buffer A containing CHAPS [0.3%] detergent. 
Protein levels in each cell type were normalized after performing protein assays with the 
Bradford assay. IgG control Sepharose beads (CST) or Rictor-conjugated Sepharose 
beads (CST) were washed 2x with PBS, blocked ~1 hr in PBS containing 2% bovine 
serum albumin (BSA) to reduce non-specific binding, and then washed in PBS 2x more. 
Whole cell lysates were then added to the washed beads, rotated at 4°C overnight, 
washed 3x in lysis buffer, and resuspended in 1x SDS-PAGE sample buffer. 
 
Mtor S2159A knock-in mice 
mTOR knock-in S2159A mice (MtorA/A) were generated using CRISPR-Cas9 genome 
editing technology and genotyped, as described (44). Mice were housed in a specific 
pathogen-free facility with a 12-hour light/12-hour dark cycle and given free access to 
food and water. All animal use was in compliance with Institutional Animal Care and Use 





Isolation and immortalization of MEFs 
Male and female heterozygous Mtor+/A mice were mated, and MEFs from plugged 
females were isolated on day 13.5 of pregnancy, generally as described (327,328). 
Dissected embryos were washed with 3x in PBS pH 7.4 and minced with fine scissors in 
the presence of trypsin-EDTA. The minced tissue was titrated with 5 mL serological and 
fine-tip Pasteur pipettes to prepare a homogenate and transferred into a 15 mL conical 
tube containing 8 mL DMEM. The homogenate was centrifuged 4 min at 300g, and the 
supernatant was discarded. The pellet was washed 1x in PBS pH 7.4 and resuspended 
in complete medium (DMEM/FBS [10%] containing 50 U/mL penicillin and 50 µg/mL 
streptomycin). The resuspended cells were transferred to a 10 cm culture dish with 
fresh complete medium and incubated at 37°C in a humidified atmosphere containing 
5% CO2. The MEFs were washed 1x with PBS pH 7.4, detached with 0.05% trypsin-
EDTA, centrifuged 4 min at 300g, and transferred to a 15 cm culture dish. At 
confluency, the MEFs were trypsinized and aliquoted to multiple cryovials for long-term 
storage in liquid N2. MEFs were immortalized spontaneously through serial passaging. 
As they reached confluency in 15 cm culture dishes following isolation, primary MEFs 
were plated into 10 cm culture dishes at a 1:9 split ratio into 10 ml complete medium 
(passage #2). Upon reaching confluency, the MEFs, were again, passaged into 10 cm 
culture dishes with a split ratio of 1:3. This process was repeated every 3-4 days until 
reaching senescence (approximately passage 5-7). Culture media was replaced every 
3-4 days, and the cells were trypsinized and transferred into a new culture dish once a 




every 3-4 days until cell number doubled approximately every 24-30 hrs. MEFs were 
genotyped as described (44) using dissected head tissue. 
 
Isolation of primary bone marrow derived macrophages (BMDMs) 
Bone marrow from 8-14 week old Mtor+/+ and MtorA/A mice was harvested by flushing 
femora and tibiae with ice-cold PBS pH 7.4 using a 30G needle under sterile conditions. 
Bone marrow cells were suspended in MEM with L-glutamine supplemented with 10% 
HI-FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, and 20 ng/ml M-CSF (R&D Systems; 
#416-ML) and plated into 6-well tissue culture plates. Cells were incubated at 37°C in 
5% CO2, and medium was replaced every other day until day 5, at which point the 
monocytes had differentiated into macrophages. Macrophages were studied at 
approximately 80% confluency.  
 
In vivo poly (I:C) treatment of mice 
Mtor+/+ and MtorA/A mice (mostly C57BL6) (12 weeks old) fed a normal chow diet were 
fasted (5 hr) and injected with saline or poly (I:C) [10 mg/kg-BW] (2 hr). Spleen tissue 
was isolated, homogenized, and analyzed by western blotting. A motorized tissue 
homogenizer (Tissue Ruptor, Qiagen) was used to homogenize whole spleen in 1 ml 
ice-cold RIPA buffer that contained protease and phosphatase inhibitors. Lysate was 
incubated on ice (10 min), centrifuged at 13,200 rpm (15 min, 4°C), and supernatant 
was collected. A DC (Detergent Compatible) protein assay (Bio-Rad; #5000111) was 





Western blot editing, quantification, and statistical analysis 
Western blot images were prepared for publication using Adobe Photoshop. Only the 
parameters levels, brightness, and contrast were employed to fine-tune exposure time 
and band sharpness. Importantly, these parameters were adjusted equivalently across 
the entire blot, and the final image shown reflects the raw image. In certain panels, thin 
dotted lines indicate excision of an irrelevant lane(s) from a western blot. Western blot 
signals were quantitated using FIJI to measure integrated densities of protein bands. 
The ratios of phosphorylated proteins over cognate total protein were calculated and 
normalized as indicated in the figure legends. Statistical significance was tested using 
paired Student’s t-test assuming equal variances. Error bars represent either standard 








Figure 2.1: TBK1 null MEFs exhibit significantly impaired EGF-stimulated Akt 
S473 phosphorylation. TBK1+/+ and TBK1-/- MEFs were serum starved overnight (20 
hr), pre-treated with Torin1 (T) [100 nM] (30 min), and stimulated without (-) or with (+) 
EGF [50 ng/mL] for the indicated times (in minutes, min). Whole cell lysates (WCLs) 
were immunoblotted with the indicated antibodies. Graph: Quantification of results. 
Mean ratio +/- SD of Akt P-S473 over total-Akt from three independent experiments, 
normalized as percent of maximal (+EGF 5 min in TBK1+/+ MEFs set to 100%). 
Statistical significance was measured using paired Student’s t-test (assuming equal 





Figure 2.2: TBK1 null MEFs exhibit reduced EGF stimulated Akt T308 
phosphorylation. TBK1+/+ and TBK1-/- MEFs were serum starved overnight (20 hr), 
pre-treated with Torin1 (T) [100nM] (30 min), and stimulated without (-) or with (+) EGF 






Figure 2.3: Stable expression of Flag-TBK1 WT rescues impaired EGF-stimulated 
Akt S473 phosphorylation in TBK1 null MEFs. TBK1+/+ MEFs, TBK1-/- MEFs, and 
clones of TBK1-/- MEFs stably expressing Flag-TBK1 were serum starved, pre-treated 
with Torin1 [100 nM] (30 min), and stimulated without (-) or with (+) EGF [50 ng/mL] for 






Figure 2.4: Stable expression of wild type (WT), but not kinase dead (KD), Flag-
TBK1 rescues impaired EGF-stimulated Akt S473 phosphorylation in TBK1 null 
MEFs. Pools of drug resistant TBK1-/- MEFs stably expressing wild type or kinase dead 





Figure 2.5: Amlexanox significantly blunts EGF-stimulated mTORC2 signaling in 
MEFs. TBK1+/+ MEFs were serum starved overnight (20 hr), pre-treated with amlexanox 
(Am) [100 mM] (2 hr) or Torin1 (T) [100 nM] (30 min), and stimulated with EGF as in Fig 
2.1. Whole cell lysates were immunoblotted with the indicated antibodies. Graph: 
Quantification of results. Mean ratio +/- SD of Akt P-S473 over total-Akt from five 
independent experiments, normalized as percent of maximal (+EGF 10 min set to 
100%). Statistical significance was measured using Student’s paired t-test (assuming 






Figure 2.6: Amlexanox significantly blunts EGF stimulated mTORC2 signaling in 
HEK293 cells. HEK293 cells were analyzed as in Fig 2.5. Graph: Quantification of 
results. Mean ratio +/- SEM of Akt P-S473 over total- Akt were calculated from five 













Figure 2.7: Torin1 profoundly reduces EGF stimulated Akt S473 phosphorylation 
over an EGF time course. TBK1+/+ and TBK1-/- MEFs were serum starved overnight 
(20 hr), pre-treated with Torin1 (T) [100 nM] (30 min), and stimulated without (-) or with 
(+) EGF [50 ng/mL] for the times indicated (in minutes, min). Whole cell lysates (WCLs) 
were immunoblotted with the indicated antibodies. 
 
 
Figure 2.8: Overexpression of Flag-TBK1 WT increases Akt P-S473 in a largely 
Torin1-sensitive manner. HEK293 cells were transfected with increasing amounts of 




complete media were treated with Torin1 (T) [100 nM] (30 min). WCLs were 
immunoblotted with the indicated antibodies. 
 
 
Figure 2.9: Co-expression of Flag-TBK1 WT and Flag-HA-Akt increases Akt S473 
phosphorylation in a Torin1-insensitive manner. HEK293 cells were co-transfected 
with increasing amounts of Flag-TBK1 ([0-1.4 mg] per 60 mm plate) together with a 
constant amount of Flag-HA-Akt [0.1 mg] in duplicate. Cells were treated with Torin1 
and analyzed as in Fig 2.8. 
 
 
Figure 2.10: Recombinant TBK1 phosphorylates His-Akt1 in vitro. Recombinant, 
active TBK1 (re-TBK1) [50 ng] and His-Akt1 [50 ng] were incubated together in an in-
vitro kinase (IVK) reaction with ATP at 30°C for 30 min, as indicated. The IVK reaction 
in lane 3 included pre-treatment with BX-795 (BX) [15 mM] for 30 min prior to initiation 









Figure 2.11: Recombinant TBK1 phosphorylates GST-mTORf in vitro. Re-TBK1 
[100 ng] was incubated with GST-mTORf [50 ng] at 30°C for 30 min, as indicated. As in 
Fig 2.10, the IVK reaction in lane 3 included pre-treatment with BX-795 (BX) [15 mM]. 
IVK reactions were immunoblotted with the indicated antibodies.   
 
 
Figure 2.12: Recombinant TBK1 phosphorylates Myc-mTOR wild type but not 
S2159A in vitro. HEK293 cells were transfected with vector control (-), Myc-mTOR wild 
type (WT), or Myc-mTOR S2159A. mTOR was immunoprecipitated (IP) with Myc-9E10 
antibody and subjected to IVK reactions with re-TBK1 [50 ng] per reaction, as in Figs 













Figure 2.13: Ku-0063794 reduces, while amlexanox does not affect, EGF-
stimulated Akt S473 phosphorylation in Rictor null MEFs stably expressing vector 
control. Rictor-/- MEFs rescued with vector control (V) or HA-Rictor were serum starved 
overnight (20 hr), pre-treated with amlexanox (Am) [100 mM] (2 hr) or Ku-0063794 (Ku) 
[100 nM] (30 min), and stimulated without (-) or with (+) EGF [50 ng/mL] for 10 min. 
Whole cell lysates (WCLs) were immunoblotted with the indicated antibodies. SE, short 





Figure 2.14: shRNA-mediated knockdown of TBK1 reduces EGF-stimulated Akt 
S473 phosphorylation in Rictor null MEFs. Rictor-/- MEFs were transduced with 
lentiviral particles encoding scrambled (Scr) shRNA or an shRNA targeting TBK1 and 
selected in puromycin. The MEFs were then serum starved overnight (20 hr), pre-
treated with Torin1 (T) [100 nM] (30 min), and stimulated without (-) or with (+) EGF [50 









Figure 2.15: mTOR S2159A knock-in MEFs exhibit significantly impaired EGF-
stimulated Akt S473 phosphorylation. Immortalized mTOR+/+ and mTORA/A MEFs 
(pair #1) were serum starved overnight (20 hr.),  pre-treated with Torin1 (T) [100 nM] 
(30 min.), and stimulated without (-) or with (+) EGF [50 ng/mL] for the indicated times 
(in minutes, min). Whole cell lysates (WCLs) were immunoblotted with the indicated 
antibodies. Graph: Quantification of results. Mean ratio +/- SD of Akt P-S473 over total-
Akt from four independent experiments, normalized as percent of maximal (+EGF 5 min. 
in mTOR+/+ MEFs set to 100%). Statistical significance of differences was measured 











Figure 2.16: mTOR S2159A knock-in MEFs exhibit reduced EGF-stimulated Akt 
T308 phosphorylation. Immortalized mTOR+/+ and mTORA/A MEFs (Pair #1) were 
serum starved overnight (20 hr), pre-treated with Torin1 (T) [100nM] (30 min), and 
stimulated without (-) or with (+) EGF [50 ng/mL] for the indicated times. Whole cell 





Figure 2.17: A second immortalized pair of wild mTOR S2159A knock-in MEFs 
exhibit impaired EGF-stimulated Akt P-S473. Immortalized mTOR+/+ and mTORA/A 








Figure 2.18: EGF does not increase TBK1 activation loop site (S172) 
phosphorylation in mTOR MEFs. mTOR+/+ and mTORA/A MEFs (pair #1) were serum 
starved and stimulated with EGF for the times indicated, as in Fig 2.15. RAW264.7 
macrophages in complete media were stimulated without (-) or with (+) LPS [100 ng/mL] 
(60 min.) to serve as a positive control for TBK1 P-S172 western blotting. WCLs from 
mTOR MEFs and RAW264.7 macrophages were resolved on the same gel and 






Figure 2.19: EGF does not increase TBK1 S172 phosphorylation in TBK1 wild type 
MEFs. TBK1+/+ and TBK1-/- MEFs were serum starved overnight and stimulated with 
EGF for the indicated times, as in S2A. RAW264.7 macrophages in complete media 
(DMEM/FBS [10%]) were stimulated without (-) or with LPS [100 ng/mL] (1 hr) to serve 
as a positive control for TBK1 P-S172 western blotting. WCLs from MEFs and 
RAW264.7 macrophages were resolved on the same gel and immunoblotted with the 











Figure 2.20: Recombinant TBK1 phosphorylates mTOR S2159 within mTORC2 in 
vitro. Rictor was immunoprecipitated from HEK293 cells and incubated with 
recombinant, active TBK1 (re-TBK1) [100 ng] for 30 min at 30°C. The IVK reaction in 





Figure 2.21: TBK1 co-immunoprecipitates with mTORC2 (Rictor/mTOR). Whole cell 
lysates from TBK1+/+ and TBK1-/- MEFs cultured in complete media (DMEM/FBS) were 
incubated with Sepharose beads conjugated to either control IgG or anti-Rictor 
antibodies overnight at 4°C. The immunoprecipitates (IPs) and whole cell lysates 






Figure 2.22: EGF does not increase mTOR S2159 phosphorylation in TBK1 wild 
type MEFs and mTOR S2159 phosphorylation is reduced in TBK1 null MEFs. 
mTOR was immunoprecipitated from TBK1+/+ and TBK1-/- MEFs that had been serum 
starved overnight and stimulated with EGF [25 ng/mL] (10 min). IPs and WCLs were 




Figure 2.23: EGF does not increase mTOR S2159 phosphorylation in mTOR wild 
type MEFs and mTOR S2159A knock-in MEFs completely lack mTOR S2159 
phosphorylation. mTOR was immunoprecipitated from mTOR+/+ and mTORA/A MEFs 









Figure 2.24: TBK1 is required for EGF to increase mTORC2 intrinsic catalytic 
activity toward His-Akt in vitro. Rictor was immunoprecipitated (IP) from TBK1+/+ and 
TBK1-/- MEFs that had been serum starved overnight, pre- treated with Torin1 [100 nM] 
(30 min), and stimulated with EGF [50 ng/mL] (10 min). The immune complexes were 
washed and subjected to in vitro kinase (IVK) reactions with His-Akt1 [100 ng] substrate 
and ATP [500 mM] at 30°C for 30 min. Torin1 was included in the IVK reactions from 
cells pre-treated with Torin1, as indicated (T on the blot). IVKs and whole cell lysates 






Figure 2.25: mTOR S2159 phosphorylation is required for EGF to increase 
mTORC2 intrinsic catalytic activity toward His-Akt in vitro. Rictor was 
immunoprecipitated from mTOR+/+ and mTORA/A MEFs (pair #1) that had been treated 
with EGF.  IVK reactions were performed on the immune complexes and analyzed as in 
Fig 2.24, except that only certain IVK reactions, but not the cells, were treated with 
Torin1, as indicated (T on the blot). Graph: Quantification of results. Mean ratio +/- SEM 
of the fold increase in Akt P-S473 over total-Akt1 from four independent experiments, 
normalized within each genotype, setting the - EGF condition to 1.0. Statistical 




**p < .01, comparing -/+ EGF in mTOR+/+ MEFs; “ns”, not significant, comparing -/+ 




Figure 2.26: TBK1 is required for EGF to increase mTOR S2481 
autophosphorylation within mTORC2. Rictor was immunoprecipitated from TBK1+/+ 
and TBK1-/- MEFs that had been serum starved overnight and stimulated with EGF [50 







Figure 2.27: mTOR S2159 phosphorylation is required for EGF to increase mTOR 
S2481 autophosphorylation within mTORC2. Rictor was immunoprecipitated from 
mTOR+/+ and mTORA/A MEFs (pair #1) that had been treated with EGF and Torin1, as in 
Fig 2.24. IPs and WCLs were immunoblotted with the indicated antibodies. Graph: 
Quantification of results. Mean ratio +/- SEM of the fold increase in mTOR P-S2481 
over total-mTOR from three independent experiments. *p < .05, comparing -/+ EGF in 











Figure 2.28: mTOR S2159 phosphorylation and TBK1 are required steady state 
mTORC2 and mTORC1 signaling in complete media. mTOR+/+ vs. mTORA/A MEFs 
(pair #1) and TBK1+/+ vs. TBK1-/- MEFs were cultured in complete media (DMEM/FBS 
[10%]). At ~80% confluency, cells were re-fed with complete media for 1.5 hr, treated 
without or with Torin1 (T) [100 nM] (30 min), and lysed. Whole cell lysates (WCLs) were 




Figure 2.29: mTOR S2159 knock in MEFs exhibit profoundly reduced FBS-
stimulated Akt S473 phosphorylation. mTOR+/+ and mTORA/A MEFs (pair #1) were 
serum starved overnight (20 hr), pre-treated with Torin1 (T) [100nM] (30 min.), and 
stimulated without (-) or with (+) FBS [10% final] for the indicated times. WCLs were 





Figure 2.30: mTOR S2159 knock in MEFs exhibit profoundly reduced PDGF-
stimulated Akt S473 phosphorylation. mTOR+/+ and mTORA/A MEFs (pair #1) were 
serum starved overnight and treated as in Fig 2.29, except they were stimulated with 






Figure 2.31: mTOR S2159 knock in MEFs exhibit profoundly reduced insulin-
stimulated Akt S473 phosphorylation. mTOR+/+ and mTORA/A MEFs (pair #1) were 
serum starved overnight and treated as in Fig 2.29, except they were stimulated with 









Figure 2.32: Diverse growth factors do not increase TBK1 P-S172 in mTOR MEFs. 
mTOR+/+ and mTORA/A MEFs (pair #1) were serum starved overnight and stimulated 
without (-) or with (+) FBS [10%], PDGF [10 ng/mL], or insulin [100 nM] (10 min). 
RAW264.7 macrophages in complete media (DMEM/FBS [10%]) were stimulated 
without (-) or with (+) LPS [100 ng/mL] (1 hr) to serve as a positive control for TBK1 P-
S172 western blotting. Whole cell lysates from MEFs and RAW264.7 macrophages 
were resolved on the same gel and immunoblotted with the indicated antibodies. Note 






Figure 2.33: mTOR S2159 phosphorylation and TBK1 are required both for amino 
acid-induced mTORC1 signaling and overall mTORC2 signaling. mTOR+/+ vs. 
mTORA/A MEFs (pair #1) and TBK1+/+ vs. TBK1-/- MEFs, cultured in complete media 
(DMEM/FBS [10%]), were amino acid deprived in DMEM lacking all amino acids but 
containing 10% dialyzed FBS (dFBS) (50 min). MEFs were then stimulated with a 
mixture of 1x total amino acids (pH 7.4) (10 min.). WCLs were immunoblotted with the 
indicated antibodies. SE, short exposure; LE, long exposure. 
 
 
Figure 2.34: Inhibition of PI3K (with BYL-719), TBK1 (with amlexanox), or mTOR 
(with Ku- 0063794) reduces mTORC2 signaling in RAW264.7 macrophages in 
response to poly (I:C). RAW264.7 macrophages, cultured in complete media 
(DMEM/FBS [10%]), were pre-treated with BYL-719 [10 mM] (30 min), amlexanox [100 









Figure 2.35: Inhibition of the TBK1/IKKe with BX-795 reduces mTORC2 signaling 
in RAW264.7 macrophages in response to poly(I:C). RAW264.7 macrophages, 
cultured in complete media (DMEM/FBS [10%]), were pre- treated with the TBK1/IKKe 
inhibitor BX-795 (BX) [10 mM] (30 min) as well as amlexanox (Am) [100 mM] (1 hr) and 
Ku-0063794 (Ku) [100 nM] (30 min) and stimulated without (-) or with (+) poly(I:C) [30 






Figure 2.36: mTOR S2159 phosphorylation and TBK1 activity both promote 
mTORC2 signaling in primary BMDMs in response to poly(I:C). Primary bone 
marrow derived macrophages (BMDMs) derived from Mtor+/+ and MtorA/A mice were 
cultured in complete media (DMEM/FBS [10%]), pre-treated with Ku-0063794 [100 nM] 
(30 min) or amlexanox [100 mM] (1 hr), and stimulated without (-) or with (+) poly(I:C) 
[30 mg/mL] (10 min). WCLs were immunoblotted with the indicated antibodies. 
 
 
Figure 2.37: mTOR S2159 phosphorylation is required for mTORC2 signaling in 
mouse spleen tissue in response to poly(I:C) treatment in vivo. Mtor+/+ and MtorA/A 
mice were fasted 5 hr and injected intraperitoneally with poly(I:C) [10 mg/kg-BW] (2 hr). 

























 Collectively, these data demonstrate that TBK1 functions as a novel direct 
upstream activator of mTORC2. Through site specific phosphorylation of mTOR-S2159 
within mTORC2, TBK1 provides an essential input in parallel to growth factor receptor 
signaling to promote mTORC2 intrinsic catalytic activity and downstream signaling to 
Akt. MEFs genetically lacking TBK1 display significantly reduced EGF-stimulated 
mTORC2 signaling, and inhibition of TBK1 with amlexanox significantly reduced EGF-
stimulated mTORC2 signaling in MEFs and HEK293 cells. MEFs harboring an mTOR-
S2159A mutation also displayed significantly impaired EGF-stimulated mTORC2 and 
mTORC1 signaling. Endogenous TBK1 and mTORC2 interact in intact cells, TBK1 
phosphorylated mTOR-S2159 within mTORC2 in vitro, TBK1 knockout MEFs display 
reduced mTOR-S2159 phosphorylation, and mTORA/A MEFs completely lack mTOR-
S2159 phosphorylation. mTOR-S2159 phosphorylation not only promotes mTORC2 and 
mTORC1 signaling in response to EGF, but also FBS, PDGF, and insulin, indicating 
that TBK1-mediated mTOR phosphorylation likely represents a general mechanism 
mediating growth factor activation of mTOR signaling. In contrast, TLR-3 engagement 
by viral- or synthetic-derived dsRNA (i.e. poly (I:C)) activates TBK1 by increasing 
activation loop phosphorylation on TBK1 P-S172, which in turn promotes mTORC2 and 




TBK1-activating innate immune agonists do in macrophages, implies that TBK1 
assumes diverse roles/functions depending on the cell type, context, and stimulus.   
 This idea is supported by the fact that other groups have reported that growth 
factors activate TBK1. First, Ou et al concluded that EGF activates TBK1 in MEFs 
based on data that TBK1 immunoprecipitated from EGF-stimulated MEFs increased P-
S473 on recombinant His-Akt1 in vitro. This data is weak, because it lacked essential 
controls, namely a stimulated sample pre-treated with a TBK1 inhibitor as well as a no 
antibody negative control (199). Interestingly, that was the only experiment in the entire 
paper reporting on a role for growth factors in increasing TBK1 kinase activity, and there 
was no assessment of TBK1 P-S172 in MEFs stimulated with EGF or other growth 
factors. This, coupled with our data demonstrating that EGF, FBS, PDGF, and insulin 
fail to increase TBK1 P-S172 in TBK1 and mTOR MEFs suggests that growth factors 
likely do not activate TBK1 in MEFs. However, this does not rule out the possibility that 
growth factors activate TBK1 in other cell types/contexts. Indeed, Zhu et al 
demonstrated that growth factors (EGF, FBS, and insulin) increase TBK1 P-S172 in 
human lung adenocarcinoma cell lines and that EGF increases TBK1 P-S172 through 
the adaptor molecule TBKBP1 (296). Mechanistically, TBK1 interacted with TBKBP1 to 
engage a signaling complex nucleated by the growth factor responsive kinase, protein 
kinase C theta (PKCq), and the adaptor, CARD10, which leads to PKCq-mediated 
activation of TBK1 in response to growth factors (296). Interestingly, Zhu did not report 
on TBK1 P-S172 status or whether or not TBKBP1 participates in TBK1 activation in 
MEFs stimulated with growth factors, likely because growth factors do not activate 




stimulated mTORC1 and mTORC2 signaling, precisely consistent with our data 
indicating an important role for TBK1 in growth factor-stimulated mTORC1 and 
mTORC2 signaling. This suggests that either the basal kinase activity of TBK1 or a 
kinase-independent function of TBK1, such as a scaffold function, promotes growth 
factor-stimulated mTORC1 and 2 signaling in MEFs. Our data demonstrating that wild 
type, and not kinase dead TBK1, rescues EGF-stimulated mTORC1 and mTORC2 
signaling in TBK1-/- MEFs suggests that the kinase activity of TBK1 profoundly 
contributes to growth factor-mediated activation of mTOR signaling. Moreover, our data 
demonstrating that mTOR-S2159 phosphorylation is detectable in MEFs, is reduced in 
MEFs lacking TBK1 or MEFs harboring an mTOR-S2159A mutation, and does not 
increase in response to EGF strengthens the plausible conclusion that, while EGF, FBS, 
PDGF, and insulin do not increase P-TBK1-S172, basal TBK1 kinase activity is 
necessary and sufficient for growth factors to robustly activate mTORC2.  
 Zhu et al also reported that, while shRNA-mediated knockdown of TBKBP1 in 
A549 lung cancer cells impairs TBK1 activation by EGF, TBKBP1 reduction has no 
effect on TBK1 activation by TBK1-activating innate immune agonists such as bacterial 
LPS and poly (I:C) (296). This suggests that, depending on the cell type, context and 
stimulus, TBK1 engages different adaptors to facilitate its activation in discrete cellular 
locations. Similar to the case concerning growth factors, no data were presented 
investigating a role for TBKBP1 in TBK1 activation in MEFs in response to TBK1-
activating innate immune agonists, likely because TBKBP1 is also dispensable for these 
stimuli to activate TBK1. However, consistent with our data, TBK1 knockout MEFs 




agonists. The ability of TBK1 to engage different adaptors in different cell types and 
contexts warrants further investigation, as it will provide additional clarity regarding 
potential cell type- and stimulus-specific roles for known and unknown TBK1 adaptors, 
as well as providing more concrete evidence to explain our data demonstrating that 
growth factors do no increase P-TBK1-S172. Based on the collective data, a viable 
hypothesis is that in MEFs TBKBP1 is dispensable for TBK1 activation by growth 
factors and innate immune agonists, likely attributed to differences in cell type (MEFs vs 
oncogenic Kras-driven lung cancer cells) or context (transformed vs oncogenic). Also, 
the fact that lung cancer is among the many cancer types strongly reliant on aberrant 
growth factor receptor signaling for proliferation and survival buttresses this hypothesis. 
Lastly, this likely provides a rational explanation for why TBK1 knockout in MEFs 
impairs growth factor-stimulated mTORC2 signaling, while growth factor-stimulated 
mTORC2 signaling in lung cancer cells appears to be TBK1 independent.  
   Numerous TBK1 interacting adaptors have been identified and characterized as 
critical participants in innate immune signal propagation following cellular detection of 
microbial stimuli. TBK1 engages several distinct adaptors via its C-terminal adaptor 
binding domain (located within the coiled-coil region of the scaffold/dimerization domain) 
to orchestrate the innate immune response, including TANK, NAP1, and the TRAF 
adaptors (200,329). The extent to which adaptors participate in TBK1-mediated signal 
transduction in other contexts such as growth factor receptor signaling remains elusive. 
In addition to Zhu, Uhm et al reported that TBK1 functions as a key kinase as part of an 
adaptor-like complex known as the exocyst complex, where, in response to insulin-




transporter GLUT4 to the plasma membrane (282). These represent perhaps the only 
reports of TBK1 directly engaging other adaptors or adaptor-like complexes to 
transduce signals outside of the context of innate immune signaling. Thus, deciphering 
the mechanistic details of TBK1 involvement in crosstalk with pathways outside of 
innate immunity may require the identification of new adaptor molecules. Moreover, 
adaptor-mediated recruitment of TBK1 remains an important regulatory mechanism for 
achieving locally restricted activation of TBK1 to, as a way to circumvent aberrant TBK1 
activity.  
 Cooper et al recently reported that TBK1, through association with a complex 
comprised of mTORC1 and mTORC1 regulatory proteins, promotes amino acid-
stimulated mTORC1 signaling, in part by activating Akt. This is consistent with our data 
demonstrating that, while amino acids increase mTORC1 signaling in TBK1 knockout 
and mTORA/A MEFs, both basal and amino acid-stimulated mTORC1 signaling are 
profoundly reduced in these cells. Interestingly, Cooper et al reports that in TBK1 
knockout MEFs or wild type MEFs or cancer cell lines treated with TBK1 inhibitors, Akt 
P-S473 (mTORC2 signaling) is also reduced. Thus, they render the conclusion that 
amino acids increase both Akt T308 and S473 phosphorylation in a TBK1-dependent 
manner. This starkly contrasts with our data in TBK1 knockout MEFs, which 
demonstrate reduced basal Akt P-S473 relative to wild type MEFs that is not increased 
upon amino acid stimulation. While the reasons for these differences remain unclear, 
the unresponsiveness of Akt P-S473 to amino acids is entirely consistent with mTOR 
dogma that mTORC2 does not participate in amino acid sensing (58,300,312-314,316).  




whole exome sequencing and gene enrichment statistical analysis, identified genes 
involved in epithelial to mesenchymal transition (EMT) to be strongly correlated with 
oncogenic KRas-harboring NSCLC subtypes that are reliant on TBK1 for survival (295). 
EMT is characterized by a loss of epithelial cell features such as E-cadherin expression 
and apical-basal polarity and a gain in mesenchymal features such as increased 
vimentin expression, motility, and cytoskeletal reorganization. Motility is a key 
metastatic phenotype that tumor cells employ to invade and occupy organs distant from 
the organ of origin. In particular, these NSCLC subtypes exhibited increased expression 
of the pro-mesenchymal gene ZEB1 (295). The identification of mutations in additional 
Ras family genes (H-Ras, N-Ras, PIK3CA, and BRAF) and Akt-mTORC1 pathway 
components suggests that cooperation among these mutant proteins, in the context of 
oncogenic Ras, is responsible for the dependence of oncogenic Ras-driven cancers on 
TBK1. The correlation between TBK1 and pro-mesenchymal genes like ZEB1 in the 
context of oncogenic KRas makes it enticing to hypothesize that TBK1 promotes 
metastasis of these types of cancers through EMT. Several independent studies link 
TBK1 to metastasis and EMT in various cancers, including those driven by oncogenic 
Ras.  
 Platelet-induced conditioning of EMT characteristics in mouse and human breast 
cancer cell lines was found to depend on TBK1 activity, and genetic depletion of TBK1 
inhibited breast cancer metastasis to the lungs of mice in a xenograft tumor model 
(330). Also, in breast cancer cells lacking sufficient levels of the microRNA, miR-200c, 
which constrains EMT through transcriptional suppression of EMT-promoting genes, 




resistance to irradiation therapy (331-334). Also, TBK1 was demonstrated to promote 
radiation induced EMT in A549 lung adenocarcinoma cells through ZEB1 (335). TBK1 
activity was increased in NRas-mutant melanoma cells, genetic depletion of TBK1 
impaired the migration and invasive properties of N-Ras mutant melanoma cells, and 
through cooperation with MEK, TBK1 was found to promote an antiapoptotic program 
(336). The integration of genetic and chemical screens and patient data focused on 
BRAF-mutant melanomas lead to the identification of a subtype that selectively depends 
on TBK1 for survival (337). Collectively, these studies strongly support the notion that 
TBK1 promotes an EMT phenotype and concomitant metastasis of various types of 
cancers, including those harboring oncogenic Ras mutations. 
 Several studies have also linked mTORC2 to EMT associated migration through 
reorganization of the cell cytoskeleton. Perhaps the earliest reports describing a role for 
mTORC2 in regulation of the cell cytoskeleton emanated in 2004. Indeed, Rictor 
depletion in NIH-3T3 cells perturbed F-actin polymerization and depolymerization, 
effectively stifling the formation and extension of actin-mediated cellular processes 
known as lamellipodia (299). In addition, mTORC2 was shown to promote GTP loading 
of Rac1, a Rho family G-protein and important regulator of F-actin dynamics associated 
with motility and migration in various cell types (299,338-342). mTORC2 was also 
reported to promote actin reorganization and attachment to the plasma membrane 
through modulation of protein kinase C alpha (PKCa) phosphorylation (26,162,343). A 
few studies have also investigated a role for mTORC2 in modulation of the actin 
cytoskeletal architecture in vivo (162,343,344). Genetic perturbation of mTORC2 in the 




T308, expression of protein kinase C isoforms (PKCa, b2, g, and e), and activation of the 
PKC substrates, GAP-43 and MARCKS, two key mediators of actin cytoskeletal 
dynamics (162,343). This same group also reported that ablation of Rictor reduced 
overall neuron size and disrupted morphology (162). Abrogation of mTORC2 function in 
the mouse hippocampus curtailed formation of filamentous actin, Rac1-GTPase activity, 
and structural integrity of neuronal synapses, ultimately affecting long term memory 
function (344).  
 mTORC2 has also been linked to metastasis in various cancer types through the 
Rac1 Rho-GTPase.  mTORC2 promotes migration and invasion of breast cancer cells 
harboring HER2 gene amplifications through bimodal mechanisms, one involving 
mTORC2 activation of PKCa, which suppresses the Rac1 inhibitor RhoGDI2, a guanine 
dissociation inhibitor that binds GDP-bound Rac1 and impedes the release of GDP, and 
another involving mTORC2 activation of Akt, which promotes Rac1 activity through the 
Rac1 guanine nucleotide exchange factor (GEF), Tiam1 (148). Genetic or 
pharmacological inhibition of mTORC2 (and mTORC1) impaired migration of colorectal 
carcinoma cells and promoted a mesenchymal to epithelial shift, concomitant with 
reduced Rac1 activity, and importantly, genetic perturbation of mTORC2 and mTORC1 
profoundly inhibited the broad formation of metastases throughout the entire mouse 
(345). In cancer cells driven by isocitrate dehydrogenase (IDH) mutations, such as 
glioma tumors, inhibition of mTORC2 reduced Rac1 activity and filamentous actin-
mediated lamellipodia (346). These studies implicate mTORC2-mediated activation of 
Rac1 in promotion of cancer cell migration, an initial step preceding tumor EMT and 




promoting actin-mediated cell migration in both normal and tumorigenic contexts, 
through PKC and Rho family G proteins.  
 Lastly, proteomic interactome analysis recently identified mTORC2 as a direct 
effector of oncogenic Ras (145,146). mTORC2 interaction with the effector binding 
domain of oncogenic Ras, but not wild type Ras, through the mTOR kinase domain, 
increased mTORC2 catalytic activity and transcription of proliferation genes, and 
promoted in vivo growth of tumors addicted to oncogenic Ras (145,146). The fact that 
both TBK1 and mTORC2 have been independently linked to EMT and oncogenic Ras 
warrants future investigation into a role for the TBK1-mTORC2 axis in promoting 
oncogenic Ras-driven tumor cell migration/metastasis, proliferation, and survival. 
Importantly, this work may reveal additional downstream effectors of oncogenic Ras that 
are more amenable to targeting, in combination therapy approaches, for treating 
notoriously difficult to eradicate oncogenic Ras-driven cancers. 
While our data demonstrate that mTORC2 represents an important signaling 
conduit through which TBK1 increases Akt P-S473, several independent groups 
reported that TBK1 functions as a direct Akt P-S473 kinase (177,199,297). Joung et al 
reported that endogenous TBK1 and Akt interact in macrophages stimulated with the 
TLR-3 and 4 agonists, poly (I:C) and bacterial LPS, respectively (297). Joung et al also 
demonstrated that genetic perturbation of Akt impaired poly (I:C)- and LPS-induced IRF-
3 activation and interferon beta production, and genetic depletion of TBK1 impaired Akt 
P-S473 (297). It is perplexing that this group failed to entertain the likelihood that 
mTORC2 functioned as the critical intermediate linking TBK1 to Akt P-S473, especially 




(11,30,347). Furthermore, our data demonstrating significant Torin-sensitivity of Akt P-
S473 in poly (I:C)-stimulated macrophages strengthens the conclusion that mTORC2 
profoundly contributes to TBK1-mediated activation of Akt.  
Ou et al demonstrated that TBK1 directly phosphorylates Akt S473 and T308 in 
various transformed and cancer cell lines, and genetic depletion of TBK1 in pancreatic 
and breast cancer cell lines significantly reduced Akt-mediated cell viability and tumor 
progression in xenograft mouse tumor models (199). Also, the absence of PDK1 (an Akt 
T308 kinase and major effector of PI3K signaling) attenuated TBK1-mediated Akt P-
T308, and in MEFs, TBK1 was essential for increasing Akt P-S473 and P-T308 in 
response to EGF and glucose, but not insulin (199). Also, Xie et al demonstrated that 
TBK1 (and IKKe) directly phosphorylate Akt on S473 and T308 in vitro, and growth 
factor activation of Akt is blunted in MEFs devoid of both TBK1 and IKKe, suggesting 
that the residual growth factor stimulated Akt P-S473 and P-T308 observed in our TBK1 
knockout MEFs is likely attributed to the presence of IKKe (177). Also, inhibition of PI3K 
with pharmacological agents profoundly blunted insulin stimulated Akt activation in 
Rictor knockout MEFs overexpressing TBK1, and both TBK1 and IKKe were markedly 
increased in cellular membrane fractions (177).  
The major proposition from both of these groups that TBK1 and IKKe represent 
Akt S473 and T308 kinases contrasts with our compelling data that instead, TBK1 (and 
likely IKKe) employ mTORC2 to increase Akt phosphorylation at these sites. Our 
observation that gross overexpression of TBK1 increases Akt P-S473 independently of 
mTOR suggests that, either direct phosphorylation of Akt by TBK1/ IKKe represents a 




conditions where TBK1/ IKKe expression are appropriately regulated, or this represents 
a potentially non-physiological mechanism that dominates in pathologic contexts where 
TBK1/IKKe are overexpressed. Also, Xie and Ou’s report that Akt P-S473 remains 
sensitive to PI3K inhibition in the presence of TBK1 overexpression supports the idea 
that TBK1 exerts its regulation on Akt through mTORC2. Lastly, Xie’s observation that 
Rictor knockout MEFs display reduced profoundly blunted growth factor-stimulated Akt 
P-S473 and P-T308 that is only partially rescued with TBK1 overexpression, again, 
buttresses the conclusion that TBK1 largely requires mTORC2 to promote Akt 
activation. Numerous independent studies previously identified several candidate Akt P-
S473 kinases, with the major caveat that a majority of these studies based their 
conclusions on overexpression of these proposed candidates (see chapter 1). Also, our 
data demonstrating that TBK1 phosphorylates two distinct substrates with dissimilar 
consensus motifs in vitro suggests that TBK1 functions as a promiscuous kinase, 
capable of phosphorylating any substrate in close proximity. Therefore, overexpression 
of TBK1 and IKKe likely dysregulates canonical regulatory mechanisms, such as 
subcellular localization, which enable TBK1 to directly phosphorylate Akt-S473 and 
T308 in a proximal-permissive manner. Indeed, lower levels of TBK1 overexpression 
promotes mTORC1 signaling to S6K1, while higher levels of TBK1 overexpression 
inhibit mTORC1, likely due to dysregulated TBK1 activity (44).  
While we report that TBK1-mediated mTOR-S2159 phosphorylation also 
promotes growth factor-stimulated mTORC1 signaling, several independent groups 
have reported on contexts where TBK1 either activates or suppresses mTORC1. 




context-specific role for TBK1 in promotion of oncogenic Ras-driven lung cancer cell 
growth through activation of mTORC1 (295). Our group demonstrated that mTOR-
S2159 promotes mTORC1 signaling in response to growth factors (EGF) and innate 
immune agonists (LPS and poly I:C), which promoted INFb production (44). Conversely, 
a study demonstrated that TBK1-mediated phosphorylation of the mTORC1 partner 
protein, Raptor, on S877 suppressed mTORC1 signaling under various conditions, 
including in response to LPS-stimulated TLR-4 activation and in human lung 
adenocarcinoma cell line A549 and colon carcinoma cell line HCT116 (50). Notably, the 
latter contrasts with Zhu et al’s report that TBK1 activates mTORC1 in response to 
growth factors in A549 cells. Another study reported that ablation of Trex and correlative 
chronic activation of TBK1 via the cGAS-STING pathway suppressed mTORC1 
signaling (348). For unknown reasons, these collective discrepancies remain unclear, 
but highlight that the diverse roles TBK1 plays in regulating mTOR seems context 
dependent. Moreover, this warrants further elucidation of the elusive upstream 
activating mechanisms governing TBK1 in these contexts. 
 Activation of TBK1 requires initial K63-linked poly-ubiquitination of its ubiquitin-
like domain (ULD) and subsequent phosphorylation of its activation loop on S172 (293). 
The mechanism(s) underlying this phosphorylation event remain unclear. However, 
current proposed models center on the ability of the C-terminal domain of TBK1 to 
exclusively bind different adaptors, depending on the cellular stimulus/context. Adaptor 
binding recruits TBK1 to discrete subcellular locations, leading to high local 
concentrations of the kinase and either one of two outcomes. The first proposed 




homodimers enables them to phosphorylate each other on S172 (207,227,349). The 
second outcome involves adaptor-mediated recruitment of TBK1 and direct 
phosphorylation by an unknown kinase (206). While the role of adaptor-mediated 
recruitment of TBK1 in the context of innate immunity is well-established, evidence for 
its role in growth factor-mediated signaling to TBK1 remains minimal. However, Zhu 
demonstrated a requirement for the adaptor, TBKBP1 (also known as SINTBAD), in 
growth factor-mediated activation of TBK1 in A549 lung adenocarcinoma cells via P-
TBK1-S172 (296). Interestingly, shRNA-mediated knockdown or knockout of TBKBP1 
or TBK1 reduced EGF-stimulated P-TBK1-S172 and mTORC1 signaling, but left 
mTORC2 signaling unperturbed (296). While the latter contradicts TBK1’s role in EGF-
stimulated mTORC2 signaling in lung cancer cells, it does emphasize the role cellular 
context might play in dictating the degree to which TBK1 functions and the downstream 
substrates it might engage and activate.  
Elucidation of a role for the TBK1-mTOR axis in the growth, proliferation, and 
survival of oncogenic Ras-driven cancers will include the following future experiments. 
CRISPR/Cas9 will be employed to generate mTOR S2159A knock in mutations in 
relevant cancer cell lines known to be addicted to oncogenic Ras (i.e. NSCLC and 
pancreatic cancer cell lines) to determine if preventing mTOR-S2159 phosphorylation 
stifles growth, proliferation, and/or increases apoptosis in these cell lines. This would 
initially support the hypothesis that TBK1-mediated mTOR-S2159 phosphorylation 
promotes oncogenic Ras-driven tumorigenesis. Also, our CRISPR mTOR+/+ and 
mTORA/A mice will be crossed with appropriate genetic mouse models of oncogenic 




and bearing oncogenic Ras and other contextually essential mutations necessary to 
recapitulate the cancer of interest, will exhibit reduced in vivo tumor growth and burden 
and metastasis (if relevant for the cancer type). In conjunction with Zhu et al 2019, it is 
likely that an oncogenic Ras-driven cancer type strongly reliant on growth factor 
receptor activation of TBK1 such as NSCLC will display reduced tumorigenicity in vivo. 
This would be a pivotal result that would lay the foundation for future experiments 
geared toward potential therapeutic targeting of TBK1-mTOR in oncogenic Ras-driven 
cancers. While the mTOR field is massive and continues to evolve, our mechanistic link 
between TBK1 and mTORC2 not only contributes critical knowledge to the upstream 
regulation of mTORC2, but it also highlights a potentially druggable pathway for 
diseases driven by aberrant TBK1 and mTORC2 activity such as oncogenic Ras-driven 
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